<SEC-DOCUMENT>0001564590-22-038025.txt : 20221118
<SEC-HEADER>0001564590-22-038025.hdr.sgml : 20221118
<ACCEPTANCE-DATETIME>20221118160540
ACCESSION NUMBER:		0001564590-22-038025
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20221114
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221118
DATE AS OF CHANGE:		20221118

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ACHIEVE LIFE SCIENCES, INC.
		CENTRAL INDEX KEY:			0000949858
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				954343413
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	033-80623
		FILM NUMBER:		221401967

	BUSINESS ADDRESS:	
		STREET 1:		22722 29TH DR. SE
		STREET 2:		SUITE 100
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98021
		BUSINESS PHONE:		425-686-1500

	MAIL ADDRESS:	
		STREET 1:		22722 29TH DR. SE
		STREET 2:		SUITE 100
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ONCOGENEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20080821

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SONUS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19950825
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>achv-8k_20221114.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-11-18T15:59:17.0988080+00:00 -->
<!-- Version            : 5.0.1.753 -->
<!-- Package ID         : 3ed8278c53cd47ce87c98e26b4d97270 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:achv="http://achievelifesciences.com/20221114" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
achv-8k_20221114.htm
</title>
</head>
<!-- NG Converter v5.0.2.73 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0000949858_20221114_20221114">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:EntityCentralIndexKey" contextRef="C_0000949858_20221114_20221114">0000949858</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="achv-20221114.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0000949858_20221114_20221114">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000949858</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-11-14</xbrli:startDate>
					<xbrli:endDate>2022-11-14</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:4pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:1pt;">&#160;</p>
<p style="text-align:center;line-height:1pt;border-top:Solid 0.75pt #000000;padding-top:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:1pt;line-height:1pt;border-top:Solid 1pt;padding-top:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 1pt #000000;padding-bottom:1pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0000949858_20221114_20221114">8-K</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 1pt #000000;padding-bottom:1pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section&#160;13 or 15(d) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">of the Securities Exchange Act of 1934 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported): <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0000949858_20221114_20221114" format="ixt:datemonthdayyearen">November 14, 2022</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 1pt #000000;padding-bottom:1pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000003" name="dei:EntityRegistrantName" contextRef="C_0000949858_20221114_20221114">ACHIEVE LIFE SCIENCES, INC.</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as Specified in Its Charter) </p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 1pt #000000;padding-bottom:1pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90.49%;">
<tr>
<td style="width:27.28%;"></td>
<td style="width:0.56%;"></td>
<td style="width:32.38%;"></td>
<td style="width:0.56%;"></td>
<td style="width:29.72%;"></td>
</tr>
<tr>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:48pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000007" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0000949858_20221114_20221114" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:28.5pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityFileNumber" contextRef="C_0000949858_20221114_20221114">033-80623</ix:nonNumeric></p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000008" name="dei:EntityTaxIdentificationNumber" contextRef="C_0000949858_20221114_20221114">95-4343413</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:48pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:48pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Incorporation)</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:28.5pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:28.5pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File Number)</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td colspan="3" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:22.78%;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntityAddressAddressLine1" contextRef="C_0000949858_20221114_20221114">1040 West Georgia</ix:nonNumeric>, <ix:nonNumeric id="F_000010" name="dei:EntityAddressAddressLine2" contextRef="C_0000949858_20221114_20221114">Suite 1030</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;margin-right:22.78%;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000011" name="dei:EntityAddressCityOrTown" contextRef="C_0000949858_20221114_20221114">Vancouver</ix:nonNumeric>, <ix:nonNumeric id="F_000012" name="dei:EntityAddressStateOrProvince" contextRef="C_0000949858_20221114_20221114">BC</ix:nonNumeric>, <ix:nonNumeric id="F_000013" name="dei:EntityAddressCountry" contextRef="C_0000949858_20221114_20221114" format="ixt-sec:countrynameen">Canada</ix:nonNumeric> </p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000014" name="dei:EntityAddressPostalZipCode" contextRef="C_0000949858_20221114_20221114">V6E 4H1</ix:nonNumeric></p></td>
</tr>
<tr>
<td colspan="3" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:22.78%;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Offices)</p></td>
<td valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s Telephone Number, Including Area Code: (<ix:nonNumeric id="F_000015" name="dei:CityAreaCode" contextRef="C_0000949858_20221114_20221114">604</ix:nonNumeric>) <ix:nonNumeric id="F_000016" name="dei:LocalPhoneNumber" contextRef="C_0000949858_20221114_20221114">210-2217</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">N/A </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former Name or Former Address, if Changed Since Last Report) </p>
<p style="text-align:center;margin-bottom:0pt;border-bottom:Solid 1pt #000000;padding-bottom:1pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:69.95%;">
<tr>
<td style="width:2.13%;"></td>
<td style="width:67.82%;"></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:WrittenCommunications" contextRef="C_0000949858_20221114_20221114" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425) </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:70.23%;">
<tr>
<td style="width:2.13%;"></td>
<td style="width:68.1%;"></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:SolicitingMaterial" contextRef="C_0000949858_20221114_20221114" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12) </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:86.34%;">
<tr>
<td style="width:2.13%;"></td>
<td style="width:84.21%;"></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:PreCommencementTenderOffer" contextRef="C_0000949858_20221114_20221114" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:85.79%;">
<tr>
<td style="width:2.13%;"></td>
<td style="width:83.66%;"></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:PreCommencementIssuerTenderOffer" contextRef="C_0000949858_20221114_20221114" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:95.86%;">
<tr>
<td style="width:36%;"></td>
<td style="width:26.67%;"></td>
<td style="width:33.19%;"></td>
</tr>
<tr>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Title of each class</span></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Trading Symbol</span></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Name of exchange on which registered</span></p></td>
</tr>
<tr>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:Security12bTitle" contextRef="C_0000949858_20221114_20221114">Common Stock, par value $0.001 per share</ix:nonNumeric></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000022" name="dei:TradingSymbol" contextRef="C_0000949858_20221114_20221114">ACHV</ix:nonNumeric></p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <ix:nonNumeric id="F_000023" name="dei:SecurityExchangeName" contextRef="C_0000949858_20221114_20221114">NASDAQ</ix:nonNumeric> Capital Market</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000005" name="dei:EntityEmergingGrowthCompany" contextRef="C_0000949858_20221114_20221114" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span> </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span> </p>
<p style="text-align:center;margin-top:4pt;line-height:1pt;border-top:Solid 0.75pt #000000;padding-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:1pt;line-height:1pt;border-top:Solid 1pt;padding-top:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#212529;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM 1.01<span style="color:#000000;"> Entry into a Material Definitive Agreement.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 14, 2022, Achieve Life Sciences, Inc., a Delaware corporation (the &#8220;<span style="text-decoration:underline;">Company</span>&#8221;), entered into subscription agreements (the &#8220;<span style="text-decoration:underline;">Subscription Agreements</span>&#8221;) with certain accredited investors (the &#8220;<span style="text-decoration:underline;">Purchasers</span>&#8221;) pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement 4,093,141 units (each, a &#8220;<span style="text-decoration:underline;">Unit</span>&#8221;), each consisting of (i) two shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;<span style="text-decoration:underline;">Common Stock</span>&#8221;), and (ii) a warrant to purchase one share of Common Stock (the &#8220;<span style="text-decoration:underline;">Warrants</span>&#8221;), at an offering price of $4.625 per Unit, for aggregate gross proceeds of approximately $18.9 million (the &#8220;<span style="text-decoration:underline;">Offering</span>&#8221;). Lake Street Capital Markets, LLC (the &#8220;<span style="text-decoration:underline;">Placement Agent</span>&#8221;), acted as the exclusive placement agent for the Offering and, pursuant to the engagement agreement between the Company and the Placement Agent (the &#8220;<span style="text-decoration:underline;">Placement Agent Agreement</span>&#8221;), will receive a cash commission equal to 5% of the gross proceeds from the sale of the Units. The net proceeds to the Company, after deducting Placement Agent expenses and commissions and estimated offering expenses payable by the Company, will be approximately $17.9 million.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each Warrant is exercisable beginning on the six (6) month anniversary of the initial closing date of the Offering (the &#8220;<span style="text-decoration:underline;">Initial Exercise Date</span>&#8221;), through the Warrant expiration date, which is the seven (7)&#160;year anniversary of the initial closing date of the Offering, except that the Warrants cannot be exercised by a Warrant holder if, after giving effect thereto, such Warrant holder would beneficially own more than 19.99% of the outstanding Common Stock, subject to certain adjustments. The Warrants issued pursuant to the Subscription Agreements are exercisable at a price per share of Common Stock of $4.50, subject to adjustment. Additionally, subject to certain exceptions, if, after the Initial Exercise Date, (i)&#160;the volume weighted average price of the Common Stock for each of 30 consecutive trading days (the &#8220;<span style="text-decoration:underline;">Measurement Period</span>&#8221;), which Measurement Period commences on the closing date, exceeds 300% of the exercise price (subject to adjustments for stock splits, recapitalizations, stock dividends and similar transactions), (ii)&#160;the average daily trading volume for such Measurement Period exceeds $500,000 per trading day and (iii)&#160;certain other equity conditions are met, and subject to a beneficial ownership limitation, then the Company may call for cancellation of all or any portion of the Warrants then outstanding. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Subscription Agreements, on November 18, 2022, the Company entered into a registration rights agreement (the &#8220;<span style="text-decoration:underline;">Registration Rights Agreement</span>&#8221;) with the Purchasers, under which the Company is required to file a registration statement within 60 days following the final closing date of the Offering (the &#8220;<span style="text-decoration:underline;">Registration Statement</span>&#8221;). The Registration Statement will register the resale of the Common Stock and the shares of Common Stock issuable upon exercise of the Warrants (the &#8220;<span style="text-decoration:underline;">Registrable Securities</span>&#8221;). <span style="Background-color:#FFFFFF;color:#212529;">The Registration Rights Agreement requires that the Company maintain the Registration Statement&#8217;s effectiveness until the earlier of the date that (i) the Registrable Securities have been sold or (ii) the Registrable Securities may be sold without any restrictions pursuant to Rule 144 under the Securities Act of 1933, as amended (the &#8220;</span><span style="text-decoration:underline;Background-color:#FFFFFF;color:#212529;">Securities Act</span><span style="Background-color:#FFFFFF;color:#212529;">&#8221;).</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing summaries of the Warrants, the Subscription Agreements and the Registration Rights Agreement do not purport to be complete and are subject to, and qualified in their entirety by, such documents attached as Exhibits 4.1, 10.1 and 10.2, respectively, to this Current Report on Form 8-K, and which are incorporated herein by reference. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#212529;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM 3.02 Unregistered Sales of Equity Securities</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#212529;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#212529;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The disclosure required by this Item 3.02 and included in Item 1.01 is incorporated into this Item 3.02 by reference.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#212529;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#212529;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#212529;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company offered and sold the Units and the shares of Common Stock underlying the Warrants in reliance on Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder. </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#212529;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM 8.01 Other Events </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 15, 2022, the Company issued a press release announcing the Offering, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.&#160;&#160;&#160;&#160;&#160;&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01.&#160;&#160;Financial Statements and Exhibits. </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:3.33%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) <span style="margin-left:36pt;">Exhibits</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:12.06%; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;No.</p></td>
<td valign="bottom" style="width:1.54%; border-bottom:solid 1pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:86.4%; border-bottom:solid 1pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="top" style="width:12.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:86.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:12.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:30pt;;text-indent:-10pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.1</p></td>
<td valign="bottom" style="width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top" style="width:86.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="achv-ex41_55.htm"><span style="text-decoration:underline;">Form of Common Stock Purchase Warrant.</span></a></p></td>
</tr>
<tr>
<td valign="middle" style="width:12.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:30pt;;text-indent:-10pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:86.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:12.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:30pt;;text-indent:-10pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom" style="width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:86.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="achv-ex101_54.htm"><span style="text-decoration:underline;">Form of Subscription Agreement.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:12.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:30pt;;text-indent:-10pt;;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:86.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:12.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:30pt;;text-indent:-10pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="bottom" style="width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:86.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="achv-ex102_53.htm"><span style="text-decoration:underline;">Form of Registration Rights Agreement.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:12.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:30pt;;text-indent:-10pt;;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:86.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:12.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:30pt;;text-indent:-10pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="bottom" style="width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:86.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="achv-ex991_6.htm"><span style="text-decoration:underline;">Press release of Achieve Life Sciences, Inc. dated November 15, 2022.</span></a></p></td>
</tr>
<tr>
<td valign="top" style="width:12.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:30pt;;text-indent:-10pt;;font-size:11pt;">&#160;</p></td>
<td valign="bottom" style="width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:86.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:12.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:30pt;;text-indent:-10pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom" style="width:1.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&#160;</p></td>
<td valign="top" style="width:86.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">________________________</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-right:6.67%;text-indent:0%;letter-spacing:-0.15pt;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&#160;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-right:6.67%;text-indent:0%;font-weight:bold;font-family:Times New Roman;letter-spacing:-0.15pt;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:478.8pt;;">
<tr>
<td style="width:216.3pt;"></td>
<td style="width:262.5pt;"></td>
</tr>
<tr>
<td valign="top">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACHIEVE LIFE SCIENCES, INC.</p></td>
</tr>
<tr>
<td valign="top" style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;letter-spacing:-0.15pt;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: November 18, 2022</p></td>
<td valign="top" style=" border-bottom:solid 0.75pt #000000;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;letter-spacing:-0.15pt;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ John Bencich</p></td>
</tr>
<tr>
<td valign="top">
<p style="text-align:justify;line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&#160;</p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000;">
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;letter-spacing:-0.15pt;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John Bencich</p>
<p style="line-height:12pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer (Principal Executive and Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>achv-ex41_55.htm
<DESCRIPTION>EX-4.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
achv-ex41_55.htm
</title>
</head>
<!-- NG Converter v5.0.2.73 -->
<body>

<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 4.1 </p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.&nbsp;&nbsp;THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:20.09%;"><font style="margin-left:36pt;"></font>&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">COMMON STOCK PURCHASE WARRANT</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ACHIEVE LIFE SCIENCES, INC. </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant Shares: _______<font style="margin-left:36pt;">Initial Exercise Date: _________________</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;"></font>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIS COMMON STOCK PURCHASE WARRANT (the &#8220;<font style="text-decoration:underline;">Warrant</font>&#8221;) certifies that, for value received, ______________ or its assigns (the &#8220;<font style="text-decoration:underline;">Holder</font>&#8221;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after ________________, 2023<sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup><font style="color:#000000;font-size:10pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup></font> (the &#8220;<font style="text-decoration:underline;">Initial Exercise Date</font>&#8221;) and on or prior to 5:00 p.m. (New York City time) on __________________ , 2029<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup><font style="color:#000000;font-size:10pt;"><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup></font> (the &#8220;<font style="text-decoration:underline;">Termination Date</font>&#8221;) but not thereafter, to subscribe for and purchase from Achieve Life Sciences, Inc., a Delaware corporation (the &#8220;<font style="text-decoration:underline;">Company</font>&#8221;), up to ______ shares (as subject to adjustment hereunder, the &#8220;<font style="text-decoration:underline;">Warrant Shares</font>&#8221;) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Section 1</font>.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Definitions</font>.&nbsp;&nbsp;In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Affiliate</font>&#8221; means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Bid Price</font>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest </p>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;"> NTD: To be date six months after the initial closing date.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;"> NTD: To be seven years after the initial issuance date.</font></p></td></tr></table></div>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;margin-left:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&#160; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in the &#8220;Pink Sheets&#8221; published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&#160;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</font></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#8220;<font style="text-decoration:underline;">Business Day</font>&#8221; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Commission</font>&#8221; means the United States Securities and Exchange Commission.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Common Stock</font>&#8221; means the common stock of the Company, par value $0.001 per share, and any other class of securities into which such securities may hereafter be reclassified or changed.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Common Stock Deemed Outstanding</font>&#8221; means, at any given time, the sum of (a) the number of shares of Common Stock actually outstanding at such time, plus (b) the number of shares of Common Stock issuable upon conversion or exchange of Common Stock Equivalents actually outstanding at such time, regardless of whether the Common Stock Equivalents are actually exercisable at such time; provided, that Common Stock Deemed Outstanding at any given time shall not include shares owned or held by or for the account of the Company or any of its wholly-owned subsidiaries.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Common Stock Equivalents</font>&#8221; means any securities of the Company or its subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Exchange Act</font>&#8221; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Exempt Issuance</font>&#8221;&#160;&#160;means the issuance of (a) shares of Common Stock, restricted stock units or options to employees, officers or directors of the Company pursuant to any equity plan duly adopted for such purpose by, or shares of Common Stock or options to employees, officers or consultants pursuant to an inducement grant approved by, a majority of the non-employee members of the Board of Directors or a majority of the </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">members of a committee of non-employee directors established for such purpose for services rendered to the Company, (b) securities upon the exercise or exchange of or conversion of any Securities issued pursuant to the Subscription Agreements pursuant to which this Warrant and other warrants of the Company were offered and sold, and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on the date of this Warrant, provided that such securities have not been amended since the date of this Warrant to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities (other than in connection with stock splits or combinations) or to extend the term of such securities, and (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, which such transactions shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.</font></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Person</font>&#8221; means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Securities Act</font>&#8221; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Trading Day</font>&#8221; means a day on which the Common Stock is traded on a Trading Market.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Trading Market</font>&#8221; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, or the New York Stock Exchange (or any successors to any of the foregoing).</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Transfer Agent</font>&#8221; means American Stock Transfer &amp; Trust Company, LLC, the current transfer agent of the Company, with a mailing address of 6201 <br />15<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> Avenue, Brooklyn, New York 11219 and an e-mail address of ReorgWarrants@ASTFINANCIAL.com<font style="color:#002060;">,</font> and any successor transfer agent of the Company.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">VWAP</font>&#8221; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&#160; if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;margin-left:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prices for the Common Stock are then reported in the &#8220;Pink Sheets&#8221; published by OTC Markets Group, Inc. (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)&#160;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.</font></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="text-decoration:underline;">Warrants</font>&#8221; means this Warrant and other warrants to purchase Common Stock issued by the Company in the offering in which this Warrant was issued.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Section 2</font>.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Exercise</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">a)</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Exercise of Warrant</font><font style="color:#000000;">.&nbsp;&nbsp;Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company (with a copy to the Transfer Agent (or such other office or agency that the Company may designate by notice in writing to the registered Holder at the address of the Holder appearing on the books of the Company)) of a duly executed facsimile copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Notice of Exercise</font><font style="color:#000000;">&#8221;). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&#8217;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required.&nbsp;&nbsp;Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased.&nbsp;&nbsp;The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice.&nbsp;&nbsp;</font><font style="font-weight:bold;color:#000000;">The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">b)</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Exercise Price</font><font style="color:#000000;">.&nbsp;&nbsp;The exercise price per share of Common Stock under this Warrant shall be $4.50, subject to adjustment hereunder (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Exercise Price</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Hlk118985810"></a><font style="Background-color:#auto;text-decoration:none;">c)</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Cashless Exercise</font><font style="color:#000000;"><a name="_Hlk118985810"></a>. If at the time of exercise hereof there is no effective registration statement registering the Warrant Shares, or the prospectus contained therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a &#8220;cashless exercise&#8221; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;margin-left:21.15%;text-indent:-5.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (A) = as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &#8220;regular trading hours&#8221; (as defined in Rule 600(b)(68) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&#8217;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &#8220;regular trading hours&#8221; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &#8220;regular trading hours&#8221; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &#8220;regular trading hours&#8221; on such Trading Day;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.08%;text-indent:-7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:23.08%;text-indent:-7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(B) = the Exercise Price of this Warrant, as adjusted hereunder; and </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.08%;text-indent:-7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:22.12%;text-indent:-6.73%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(X) = the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant.&nbsp;&nbsp;The Company agrees not to take any position contrary to this Section 2(c).</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:22.12%;text-indent:-6.73%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding anything herein to the contrary, on the Termination Date, this Warrant shall be automatically exercised via cashless exercise pursuant to this Section 2(c).</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:22.12%;text-indent:-6.73%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">a)</font><font style="margin-left:153pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Mechanics of Exercise</font><font style="color:#000000;">. </font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:23.08%;text-indent:6.34%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">i.</font><font style="margin-left:149pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Delivery of Warrant Shares Upon Exercise</font><font style="color:#000000;">.&nbsp;&nbsp;The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&#8217;s or its designee&#8217;s balance account with The Depository Trust Company (&#8220;</font><font style="text-decoration:underline;color:#000000;">DTC</font><font style="color:#000000;">&#8221;) through its Deposit or Withdrawal at Custodian system (&#8220;</font><font style="text-decoration:underline;color:#000000;">DWAC</font><font style="color:#000000;">&#8221;) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 promulgated under the Securities Act and this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered in the Company&#8217;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise, and, in the case of each of (i) and (iii), subject to the Company&#8217;s receipt of the aggregate Exercise Price (such date, the &#8220;</font><font style="text-decoration:underline;color:#000000;">Warrant Share Delivery Date</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise.&nbsp;&nbsp;The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable.&nbsp;&nbsp;As used herein, &#8220;</font><font style="text-decoration:underline;color:#000000;">Standard Settlement Period</font><font style="color:#000000;">&#8221; means the standard settlement period, expressed in a number of Trading Days, on the Company&#8217;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:23.08%;text-indent:5.63%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">ii.</font><font style="margin-left:149pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Delivery of New Warrants Upon Exercise</font><font style="color:#000000;">.&nbsp;&nbsp;If this Warrant shall have been exercised in part, the Company shall, at the request of the Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:23.08%;text-indent:4.91%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">iii.</font><font style="margin-left:149pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Rescission Rights</font><font style="color:#000000;">.&nbsp;&nbsp;If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section </font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise, and the Company shall return all consideration paid by the Holder for such Warrant Shares upon such rescission. Notwithstanding anything herein to the contrary, the Company shall not be required to make any cash payments to the Holder in lieu of issuance of the Warrant Shares.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:23.08%;text-indent:5.05%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">iv.</font><font style="margin-left:149pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Reserved</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:23.08%;text-indent:5.77%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">v.</font><font style="margin-left:149pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">No Fractional Shares or Scrip</font><font style="color:#000000;">.&nbsp;&nbsp;No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant.&nbsp;&nbsp;As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:23.08%;text-indent:5.05%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">vi.</font><font style="margin-left:149pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Charges, Taxes and Expenses</font><font style="color:#000000;">.&nbsp;&nbsp;Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;">, </font><font style="text-decoration:underline;color:#000000;">however</font><font style="color:#000000;">, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.&nbsp;&nbsp;The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to DTC (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:23.08%;text-indent:4.35%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">vii.</font><font style="margin-left:149pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Closing of Books</font><font style="color:#000000;">.&nbsp;&nbsp;The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">b)</font><font style="margin-left:153pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Holder&#8217;s Exercise Limitations</font><font style="color:#000000;">.&nbsp;&nbsp;The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&#8217;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&#8217;s Affiliates (such Persons, &#8220;</font><font style="text-decoration:underline;color:#000000;">Attribution Parties</font><font style="color:#000000;">&#8221;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&#160; For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with </font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.&#160; Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith.&nbsp;&nbsp; To the extent that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&#8217;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation. To ensure compliance with this restriction, each Holder will be deemed to represent to the Company each time it delivers a Notice of Exercise that such Notice of Exercise has not violated the restrictions set forth in this paragraph, and the Company shall have no obligation to verify or confirm the accuracy of such determination.&nbsp;&nbsp;In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder.&nbsp;&nbsp;For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&#8217;s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&#160; Upon the written or oral request of a Holder, the Company shall within two (2) Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&#160; In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported.&nbsp;&nbsp;The &#8220;</font><font style="text-decoration:underline;color:#000000;">Beneficial Ownership Limitation</font><font style="color:#000000;">&#8221; shall be 19.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant.&nbsp;&nbsp;The Holder, upon notice to the Company, may decrease, and subsequently increase or decrease, the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 19.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise </font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">of this Warrant held by the Holder and the provisions of this Section 2(e) shall continue to apply.&nbsp;&nbsp;Any increase in the Beneficial Ownership Limitation will not be effective until the 61</font><font style="color:#000000;"><sup style="font-size:85%;line-height:120%;vertical-align:top">st</sup></font><font style="color:#000000;"> day after such notice is delivered to the Company.&nbsp;&nbsp;The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant. </font></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">f)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Call Provision</font>.&nbsp;&nbsp;Subject to the provisions of Section 2(e) and this Section 2(f), if, after the Initial Exercise Date, (i) the VWAP for any 30 consecutive Trading Days (the &#8220;<font style="text-decoration:underline;">Measurement Period</font>,&#8221; which 30 consecutive Trading Day period shall not have commenced until after the Initial Exercise Date) exceeds $13.50 (subject to adjustment for forward and reverse stock splits, recapitalizations, stock dividends and the like after the date this Warrant is issued), (ii) the average daily volume for such Measurement Period exceeds $500,000 per Trading Day and (iii) the Holder is not in possession of any information that constitutes, or might constitute, material non-public information which was provided by the Company, any of its subsidiaries, or any of their officers, directors, employees, agents or Affiliates, then the Company may, within thirty (30) Trading Days of the end of any such Measurement Period, call for cancellation of all or any portion of this Warrant for which a Notice of Exercise has not yet been delivered (such right, a &#8220;<font style="text-decoration:underline;">Call</font>&#8221;) for consideration equal to $0.001 per Warrant Share.&nbsp;&nbsp;To exercise this right, the Company must deliver to the Holder an irrevocable written notice (a &#8220;<font style="text-decoration:underline;">Call Notice</font>&#8221;), indicating therein the portion of unexercised portion of this Warrant to which such notice applies.&nbsp;&nbsp;If the conditions set forth below for such Call are satisfied from the period from the date of the Call Notice through and including the Call Date (as defined below), then any portion of this Warrant subject to such Call Notice for which a Notice of Exercise shall not have been received by the Call Date will be cancelled at 6:30 p.m. (New York City time) on the tenth Trading Day after the date the Call Notice is received by the Holder (such date and time, the &#8220;<font style="text-decoration:underline;">Call Date</font>&#8221;).&nbsp;&nbsp;Any unexercised portion of this Warrant to which the Call Notice does not pertain will be unaffected by such Call Notice.&nbsp;&nbsp;In furtherance thereof, the Company covenants and agrees that it will honor all Notices of Exercise with respect to Warrant Shares subject to a Call Notice that are tendered through 6:30 p.m. (New York City time) on the Call Date, and in connection therewith Holder shall be entitled to receive the Black Scholes Value (as defined in Section 3(e) below) of the Warrant, or portion thereof that is being so exercised, via a corresponding reduction in the Exercise Price.&nbsp;&nbsp;The parties agree that any Notice of Exercise delivered following a Call Notice which calls less than all of the Warrants shall first reduce to zero the number of Warrant Shares subject to such Call Notice prior to reducing the remaining Warrant Shares available for purchase under this Warrant.&nbsp;&nbsp;For example, if (A) this Warrant then permits the Holder to acquire 100 Warrant Shares, (B) a Call Notice pertains to 75 Warrant Shares, and (C) prior to 6:30 p.m. (New York City time) on the Call Date the Holder tenders a Notice of Exercise in respect of 50 Warrant Shares, then (x) on the Call Date the right under this Warrant to acquire 25 Warrant Shares will be automatically cancelled, (y) the Company, in the time and manner required under this Warrant, will have issued and delivered to the Holder 50 Warrant Shares in respect of the exercises </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;margin-left:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">following receipt of the Call Notice, and (z) the Holder may, until the Termination Date, exercise this Warrant for 25 Warrant Shares (subject to adjustment as herein provided and subject to subsequent Call Notices).&nbsp;&nbsp;Subject again to the provisions of this Section 2(f), the Company may deliver subsequent Call Notices for any portion of this Warrant for which the Holder shall not have delivered a Notice of Exercise.&nbsp;&nbsp;Notwithstanding anything to the contrary set forth in this Warrant, the Company may not deliver a Call Notice or require the cancellation of this Warrant (and any such Call Notice shall be void), unless, from the beginning of the Measurement Period through the Call Date, (1) the Company shall have honored in accordance with the terms of this Warrant all Notices of Exercise delivered by 6:30 p.m. (New York City time) on the Call Date, (2) a registration statement shall be effective as to all Warrant Shares and the prospectus thereunder available for use by the Company for the resale of all such Warrant Shares by the Holder, (3) the Common Stock shall be listed or quoted for trading on the Trading Market, (4) there is a sufficient number of authorized shares of Common Stock for issuance of all Warrant Shares, and (5) the issuance of all Warrant Shares subject to a Call Notice shall not cause a breach of any provision of Section 2(e) herein.&nbsp;&nbsp;The Company&#8217;s right to call the Warrants under this Section 2(f) shall be exercised ratably among the Holders based on each Holder&#8217;s initial purchase of Warrants.</font></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Section 3</font>.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Certain Adjustments</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">a)</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Stock Dividends and Splits</font><font style="color:#000000;">. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged.&nbsp;&nbsp;Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re&#8209;classification.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">b)</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Subsequent Equity Sales</font><font style="color:#000000;">. If the Company or any subsidiary thereof, as applicable, at any time while this Warrant is outstanding, shall sell or grant any option to purchase, or sell or grant any right to reprice, or otherwise dispose of or issue (or announce any offer, sale, grant or any option to purchase or other disposition) any Common Stock or Common Stock Equivalents, at an effective price per share less than 50% of the Exercise Price then in effect (such lower price, the &#8220;</font><font style="text-decoration:underline;color:#000000;">Base Share Price</font><font style="color:#000000;">&#8221; and </font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">such issuances collectively, a &#8220;</font><font style="text-decoration:underline;color:#000000;">Dilutive Issuance</font><font style="color:#000000;">&#8221;) (it being understood and agreed that if the holder of the Common Stock or Common Stock Equivalents so issued shall at any time, whether by operation of purchase price adjustments, reset provisions, floating conversion, exercise or exchange prices or otherwise, or due to warrants, options or rights per share which are issued in connection with such issuance, be entitled to receive shares of Common Stock at an effective price per share that is less than the Exercise Price, such issuance shall be deemed to have occurred for less than the Exercise Price on such date of the Dilutive Issuance at such effective price), then simultaneously with the consummation of each Dilutive Issuance the Exercise Price shall be reduced and only reduced to equal the quotient obtained by dividing: (i) the sum of (A) the product obtained by multiplying the Common Stock Deemed Outstanding immediately prior to the Dilutive Issuance by the Exercise Price then in effect plus (B) the product obtained by multiplying the aggregate number of shares of Common Stock issued or sold (or deemed issued or sold) by the Company in the Dilutive Issuance (fully diluted) by the Base Share Price; by (ii) the sum of (A) the Common Stock Deemed Outstanding immediately prior to the Dilutive Issuance plus (B) the aggregate number of shares of Common Stock issued or sold (or deemed issued or sold) by the Company in the Dilutive Issuance (fully diluted);&nbsp;&nbsp;provided, in no event shall the Exercise Price be reduced to an amount less than 75% of the Exercise Price per share of Common Stock, subject to adjustment for stock splits and combinations (as may be adjusted, the &#8220;</font><font style="text-decoration:underline;color:#000000;">Minimum Exercise Price</font><font style="color:#000000;">&#8221;). Upon any and each adjustment of the Exercise Price as provided in Section 3(b), the number of shares of Common Stock issuable upon the exercise of this Warrant immediately prior to any such adjustment shall be increased to a number of shares equal to the quotient obtained by dividing: (i) the product of (A) the Exercise Price in effect immediately prior to any such adjustment multiplied by (B) the number of shares issuable upon exercise of this Warrant immediately prior to any such adjustment; by (ii) the Exercise Price resulting from such adjustment.&nbsp;&nbsp;Notwithstanding the foregoing, no adjustments shall be made, paid or issued under this Section 3(b) in respect of an Exempt Issuance.&#160;&#160;The Company shall notify the Holder, in writing, no later than the Trading Day following the issuance or deemed issuance of any Common Stock or Common Stock Equivalents subject to this Section 3(b), indicating therein the applicable issuance price, or applicable reset price, exchange price, conversion price and other pricing terms (such notice, the &#8220;</font><font style="text-decoration:underline;color:#000000;">Dilutive Issuance Notice</font><font style="color:#000000;">&#8221;).&#160;&#160; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">c)</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Subsequent Rights Offerings</font><font style="color:#000000;">.&nbsp;&nbsp;In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Purchase Rights</font><font style="color:#000000;">&#8221;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (</font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;">, </font><font style="text-decoration:underline;color:#000000;">however</font><font style="color:#000000;">, to the extent that the Holder&#8217;s right to participate in any such Purchase Right would result in </font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">d)</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Pro Rata Distributions</font><font style="color:#000000;">.&nbsp;&nbsp;During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#8220;</font><font style="text-decoration:underline;color:#000000;">Distribution</font><font style="color:#000000;">&#8221;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (</font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;">, </font><font style="text-decoration:underline;color:#000000;">however</font><font style="color:#000000;">, to the extent that the Holder's right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="OLE_LINK5"></a><a name="OLE_LINK6"></a><font style="Background-color:#auto;text-decoration:none;">e)</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Fundamental Transaction</font><font style="color:#000000;"><a name="OLE_LINK5"></a><a name="OLE_LINK6"></a>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock </font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a &#8220;</font><font style="text-decoration:underline;color:#000000;">Fundamental Transaction</font><font style="color:#000000;">&#8221;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Alternate Consideration</font><font style="color:#000000;">&#8221;) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Warrant).&nbsp;&nbsp;For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration.&nbsp;&nbsp;If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.&nbsp;&nbsp;Notwithstanding anything to the contrary, in the event of a Fundamental Transaction other than one in which a Successor Entity (as defined below) that is a publicly traded corporation whose stock is quoted or listed on a Trading Market assumes this Warrant such that the Warrant shall be exercisable for the publicly traded common stock of such Successor Entity, the Company or any Successor Entity shall, at the Holder&#8217;s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction, purchase this Warrant from the Holder by paying to the Holder an amount equal to the Black Scholes Value of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction using the same type or form of consideration (and in the same proportion) that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction.&nbsp;&nbsp;Any cash payment will be made by wire transfer of immediately available funds within five (5) Business Days of the Holder&#8217;s election (or, if later, on the effective date of the Fundamental Transaction). &#8220;</font><font style="text-decoration:underline;color:#000000;">Black Scholes Value</font><font style="color:#000000;">&#8221; means the value of this Warrant based on the Black and Scholes Option Pricing Model obtained from the &#8220;OV&#8221; function on Bloomberg, L.P. (&#8220;</font><font style="text-decoration:underline;color:#000000;">Bloomberg</font><font style="color:#000000;">&#8221;) determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a tenor equivalent to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected volatility equal to the lesser of 100% and the 100 day volatility obtained from the HVT function on Bloomberg as of the Trading Day immediately following the </font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">public announcement of the applicable Fundamental Transaction, (C) the underlying price per share used in such calculation shall be the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (D) a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date.&nbsp;&nbsp;The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Successor Entity</font><font style="color:#000000;">&#8221;) to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section 3(e) and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction). Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the &#8220;Company&#8221; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company herein.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">f)</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Calculations</font><font style="color:#000000;">. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">g)</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Notice to Holder</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:23.08%;text-indent:6.34%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">i.</font><font style="margin-left:162pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Adjustment to Exercise Price</font><font style="color:#000000;">. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by facsimile or e-mail a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:23.08%;text-indent:5.63%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">ii.</font><font style="margin-left:162pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Notice to Allow Exercise by Holder</font><font style="color:#000000;">. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company </font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or e-mail to the Holder at its last facsimile number or e-mail address as it shall appear upon the Warrant Register (as defined below) of the Company, at least 10 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; </font><font style="text-decoration:underline;color:#000000;">provided</font><font style="color:#000000;">, that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice.&nbsp;&nbsp;To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of its subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.&nbsp;&nbsp;The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</font></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Section 4</font>.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Transfer of Warrant</font>.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">a)</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Transferability</font><font style="color:#000000;">.&nbsp;&nbsp;Subject to compliance with any applicable securities laws and the conditions set for in Section 4(d) hereof, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.&nbsp;&nbsp;Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the </font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled.&nbsp;&nbsp;Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full.&nbsp;&nbsp;The Warrant, if properly assigned in accordance herewith, may be exercised by a new Holder for the purchase of Warrant Shares without having a new Warrant issued.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">b)</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">New Warrants.</font><font style="color:#000000;"> This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney.&nbsp;&nbsp;Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">c)</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Warrant Register</font><font style="color:#000000;">. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Warrant Register</font><font style="color:#000000;">&#8221;), in the name of the record Holder hereof from time to time.&nbsp;&nbsp;The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">d)</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Transfer Restrictions</font><font style="color:#000000;">. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144 promulgated under the Securities Act, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, to deliver a legal opinion of counsel to the transferor to the effect that the transfer is pursuant to an effective registration statement under the Securities Act or pursuant to an available exemption from, or is a transaction not subject to, the registration requirements of the Securities Act and is in accordance with applicable state securities laws.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:8.65%;text-indent:6.73%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">e)</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Representation by the Holder</font><font style="color:#000000;">. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act.</font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Section 5</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Miscellaneous</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">a)</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">No Rights as Stockholder Until Exercise</font><font style="color:#000000;">.&nbsp;&nbsp;This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">b)</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Loss, Theft, Destruction or Mutilation of Warrant</font><font style="color:#000000;">. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">c)</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Saturdays, Sundays, Holidays, etc</font><font style="color:#000000;">.&nbsp;&nbsp;If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day or Trading Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day or Trading Day, as the case may be.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">d)</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Authorized Shares</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;margin-left:15.38%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant.&nbsp;&nbsp;The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant.&nbsp;&nbsp;The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed.&nbsp;&nbsp;The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of </p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;margin-left:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment.&nbsp;&nbsp;Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.</font></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;margin-left:15.38%;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">e)</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Governing Law</font><font style="color:#000000;">. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&#8217; fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">f)</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Restrictions</font><font style="color:#000000;">.&nbsp;&nbsp;The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize </font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">g)</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Nonwaiver and Expenses</font><font style="color:#000000;">.&nbsp;&nbsp;No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#8217;s rights, powers or remedies.&nbsp;&nbsp;Without limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#8217; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_DV_C47"></a><font style="Background-color:#auto;text-decoration:none;">h)</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;"><a name="_DV_C47"></a>Notices</font><font style="color:#000000;">.&nbsp;&nbsp;Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service, addressed to the Company, at 1040 West Georgia Street, Suite 1030, Vancouver, B.C., V6E 4H1 Canada, Attention: Senior Paralegal, e-mail address: sthomson@achievelifesciences.com, or such other e-mail address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight courier service addressed to each Holder at the e-mail address or address of such Holder appearing on the books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section 5(h) prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the date of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section 5(h) on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given.&nbsp;&nbsp;Notwithstanding any other provision of this Warrant, as to any Warrant not held in certificated form, where this Warrant provides for notice of any event to a Holder, such notice shall be sufficiently given if given to DTC (or any successor depository) pursuant to the procedures of DTC (or such successor depository).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">i)</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Limitation of Liability</font><font style="color:#000000;">.&nbsp;&nbsp;No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">j)</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Remedies</font><font style="color:#000000;">.&nbsp;&nbsp;The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant.&nbsp;&nbsp;The Company agrees that monetary damages would not </font></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">k)</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Successors and Assigns</font><font style="color:#000000;">.&nbsp;&nbsp;Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.&nbsp;&nbsp;The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">l)</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Amendment</font><font style="color:#000000;">.&nbsp;&nbsp;This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holders or the beneficial owners of Warrants representing 67% of the Warrant Shares issuable under the Warrants then-outstanding as of the date such consent is sought, on the other hand.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">m)</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Severability</font><font style="color:#000000;">.&nbsp;&nbsp;Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">n)</font><font style="margin-left:108pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Headings</font><font style="color:#000000;">.&nbsp;&nbsp;The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">********************</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(Signature Page Follows)<br /></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:38.46%;"><font style="font-weight:bold;">&nbsp;</font>&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:62.8%;">
<tr>
<td style="width:62.8%;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.65pt;padding-Right:5.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">ACHIEVE LIFE SCIENCES, INC.</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.65pt;padding-Right:5.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:__________________________________________</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; Name:</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; Title:</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:38.46%;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTICE OF EXERCISE</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;">To:<font style="margin-left:36pt;">achieve life sciences, inc.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(1)</font><font style="margin-left:90pt;color:#000000;"></font><font style="color:#000000;">The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(2)</font><font style="margin-left:90pt;color:#000000;"></font><font style="color:#000000;">Payment shall take the form of (check applicable box):</font></p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;margin-left:23.08%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[&nbsp;&nbsp;] in lawful money of the United States; or</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;margin-left:23.08%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ ] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(3)</font><font style="margin-left:90pt;color:#000000;"></font><font style="color:#000000;">Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</font></p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">_______________________________</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;"></font>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Warrant Shares shall be delivered to the following DWAC Account Number:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">_______________________________</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;"></font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">_______________________________</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;"></font>&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">_______________________________</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(4)</font><font style="margin-left:90pt;color:#000000;"></font><font style="color:#000000;">The undersigned is an &#8220;accredited investor&#8221; as defined in Regulation D promulgated under the Securities Act of 1933, as amended.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;">[SIGNATURE OF HOLDER]</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name of Investing Entity: ________________________________________________________________________</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Signature of Authorized Signatory of Investing Entity<font style="font-style:normal;">: _________________________________________________</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name of Authorized Signatory: ___________________________________________________________________</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title of Authorized Signatory: ____________________________________________________________________</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: ________________________________________________________________________________________</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ASSIGNMENT FORM</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:2.24%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(To assign the foregoing Warrant, execute this form and supply required information.&nbsp;&nbsp;Do not use this form to purchase shares.)</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:2.24%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M163"></a>FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:auto;">
<tr>
<td style="width:51.26%;"></td>
<td style="width:51.27%;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.65pt;padding-Right:5.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="padding-left:5.65pt;padding-Right:5.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.65pt;padding-Right:5.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.65pt;padding-Right:5.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Please Print)</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.65pt;padding-Right:5.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Address:</p></td>
<td valign="top"  style="padding-left:5.65pt;padding-Right:5.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.65pt;padding-Right:5.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_C128"></a>Phone Number:</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email Address:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </p></td>
<td valign="top"  style="padding-left:5.65pt;padding-Right:5.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Please Print)</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">______________________________________</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-align:justify;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">______________________________________</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.65pt;padding-Right:5.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: _______________ __, ______</p></td>
<td valign="top"  style="padding-left:5.65pt;padding-Right:5.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.65pt;padding-Right:5.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holder&#8217;s Signature:<font style="text-decoration:underline;"></font></p></td>
<td valign="top"  style="padding-left:5.65pt;padding-Right:5.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.65pt;padding-Right:5.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:30pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holder&#8217;s Address:<font style="text-decoration:underline;"></font></p></td>
<td valign="top"  style="padding-left:5.65pt;padding-Right:5.65pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:30pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>achv-ex101_54.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
achv-ex101_54.htm
</title>
</head>
<!-- NG Converter v5.0.2.73 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 10.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">SUBSCRIPTION AGREEMENT</font><font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Achieve Life Sciences, Inc.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1040 West Georgia Street, Suite 1030</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vancouver, British Columbia, Canada V6E 4H1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ladies and Gentlemen:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.&#160;Subscription.<font style="font-weight:normal;">&#160;As of November 14, 2022, the undersigned (the &#8220;</font><font style="font-style:italic;">Purchaser</font><font style="font-weight:normal;">&#8221;), intending to be legally bound, hereby irrevocably agrees to purchase from Achieve Life Sciences, Inc., a Delaware corporation (the &#8220;</font><font style="font-style:italic;">Company</font><font style="font-weight:normal;">&#8221;), the number of Units (the &#8220;</font><font style="font-style:italic;">Units</font><font style="font-weight:normal;">&#8221;) set forth on the signature page hereof at a purchase price of $4.625 per Unit. Each Unit consists of (i) two (2) shares of common stock (the &#8220;</font><font style="font-style:italic;">Shares</font><font style="font-weight:normal;">&#8221;), par value $0.001 per share, of the Company (the &#8220;</font><font style="font-style:italic;">Common Stock</font><font style="font-weight:normal;">&#8221;), and (ii) one warrant to purchase one share of Common Stock (the &#8220;</font><font style="font-style:italic;">Warrant Shares</font><font style="font-weight:normal;">&#8221;) at an initial per share exercise price equal to $4.50 (each a &#8220;</font><font style="font-style:italic;">Warrant</font><font style="font-weight:normal;">&#8221; and collectively, the &#8220;</font><font style="font-style:italic;">Warrants</font><font style="font-weight:normal;">&#8221;), which will terminate seven years following the initial closing of the Offering (as defined below).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This subscription is submitted to the Purchaser in accordance with and subject to the terms and conditions described in this Subscription Agreement and the Confidential Private Placement Memorandum of the Company, dated&#160;November 14, 2022, as amended or supplemented from time to time, including all attachments, schedules and exhibits thereto (the &#8220;<font style="font-weight:bold;font-style:italic;">Memorandum</font>&#8221;), relating to the private placement offering (the &#8220;<font style="font-weight:bold;font-style:italic;">Offering</font>&#8221;) by the Company of up to 5,405,405 Units with an aggregate maximum purchase price of $25.0 million. The Units are being offered by the Company and Lake Street Capital Markets, LLC (the &#8220;<font style="font-weight:bold;font-style:italic;">Broker</font>&#8221;) on a &#8220;reasonable best efforts&#8221; basis. The minimum purchase amount is 2,162,162 Units ($10.0 million), although the Company may, in its discretion, accept subscriptions for a lesser number of Units.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Broker will receive a cash commission equal to 5.0% of the gross proceeds from the sale of the Units (the &#8220;<font style="font-weight:bold;font-style:italic;">Commission</font>&#8221;) as further described in the Placement Agent Agreement between the Company and the Broker.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The terms of the Offering are more completely described in the Memorandum and such terms are incorporated by reference herein in their entirety. Capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Memorandum.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.&#160;Payment.<font style="font-weight:normal;">&#160;The Purchaser will immediately make a wire transfer payment to the Company in the full amount of the purchase price of the Units being subscribed for (the &#8220;</font><font style="font-style:italic;">Subscription Amount</font><font style="font-weight:normal;">&#8221;) as set forth on the signature page hereto. Wire transfer instructions are set forth on </font><font style="text-decoration:underline;font-weight:normal;">Schedule 1</font><font style="font-weight:normal;"> accompanying this Subscription Agreement. Such funds will be returned promptly, without interest or offset, if the Purchaser&#8217;s subscription is not accepted by the Company for any reason or no reason, or the Offering is terminated pursuant to its terms by the Company prior to the applicable closing of the Offering.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.&#160;Deposit of Funds.<font style="font-weight:normal;">&#160;The Company shall hold all funds in escrow until such time as it closes on the corresponding subscriptions. If the Company rejects a subscription, either in whole or in part (which decision is in the Company&#8217;s sole discretion), the rejected subscription funds or the rejected portion thereof will be returned promptly to the Purchaser without interest accrued thereon.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="font-weight:normal;">&#160;</font>Deliveries.<font style="font-weight:normal;">&#160;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) On or prior to the applicable closing, the Purchaser shall deliver or cause to be delivered the following to the Company:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.23%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i) </font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">this Subscription Agreement, duly executed by the Purchaser;</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:23.08%;text-indent:-3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.23%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii) </font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the Subscription Amount, by wire transfer to the Company&#8217;s account, as set forth on&#160;<font style="text-decoration:underline;">Schedule 1</font>&#160;attached hereto;</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:23.08%;text-indent:-3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.23%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii) </font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the Registration Rights Agreement, in the form attached hereto as&#160;<font style="text-decoration:underline;">Annex A</font>, duly executed by such Purchaser; and</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:23.08%;text-indent:-3.85%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.23%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv) </font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a fully completed and duly executed Accredited Investor Certification, satisfactory to the Company, in the form attached hereto as&#160;<font style="text-decoration:underline;">Annex B.</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) On or prior to the applicable closing, the Company shall deliver or cause to be delivered the following to each Purchaser participating is such closing:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.23%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i) </font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a fully executed and compiled copy of this Subscription Agreement; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:19.23%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii) </font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">a fully executed and compiled copy of the Registration Rights Agreement.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company shall also deliver the executed Warrant in the form attached hereto as&#160;<font style="text-decoration:underline;">Annex C</font>&#160;within ten (10) trading days of the applicable closing date.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.&#160;Acceptance of Subscription.<font style="font-weight:normal;">&#160;The Purchaser understands and agrees that the Company, in its sole discretion, reserves the right to accept or reject this or any other subscription for Units, in whole or in part, and for any reason or no reason, notwithstanding prior receipt by the Purchaser of notice of acceptance of its subscription. The Company shall have no obligation hereunder until this Subscription Amount is received by the Company and the Company has executed and delivered to the Purchaser a fully executed and compiled copy of this Subscription Agreement. If such Purchaser&#8217;s subscription is rejected in whole or the Offering is terminated, all funds received from the Purchaser will be returned without interest or offset, and this Subscription Agreement shall thereafter be of no further force or effect. If such Purchaser&#8217;s subscription is rejected in part, the funds for the rejected portion of its subscription will be returned without interest or offset, and this Subscription Agreement will continue in full force and effect to the extent such Purchaser&#8217;s subscription was accepted.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.&#160;Representations and Warranties of the Purchaser<font style="font-weight:normal;">. Each Purchaser, for itself and no other Purchaser, hereby acknowledges, represents, warrants and agrees to and with the Company as follows (it being specifically acknowledged and agreed that the Broker shall be a third-party beneficiary of the following):</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:bold;font-size:18pt;margin-left:108pt;"></font><font style="color:#auto;">The Purchaser is aware that an investment in the Units involves a significant degree of risk and has carefully read and considered the matters set forth in the Memorandum, including but not limited to the section entitled &#8220;Risk Factors&#8221; in the Memorandum, and the Company&#8217;s filings with the Securities and Exchange Commission (the &#8220;</font><font style="font-style:italic;color:#auto;font-weight:bold;">SEC</font><font style="color:#auto;">&#8221;).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-weight:bold;font-size:18pt;margin-left:108pt;"></font><font style="color:#auto;">&#160;None of the securities comprising the Units, including the Shares and the Warrants offered pursuant to the Memorandum, or the Warrant Shares issuable upon conversion of the Warrants, are registered under the Securities Act of 1933, as amended (the &#8220;</font><font style="font-style:italic;color:#auto;font-weight:bold;">Securities Act</font><font style="color:#auto;">&#8221;), or any state securities laws. The Purchaser understands that the offering and sale of the Units (including the Shares and the Warrants) and the Warrant Shares issuable upon conversion of the Warrants are intended to be exempt from registration under the Securities Act, by virtue of Section 4(a)(2) thereof and the provisions of Regulation D promulgated thereunder (&#8220;</font><font style="font-style:italic;color:#auto;font-weight:bold;">Regulation D</font><font style="color:#auto;">&#8221;), based, in part, upon the representations, warranties and agreements of the Purchaser contained in this Subscription Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-weight:bold;font-size:18pt;margin-left:108pt;"></font><font style="color:#auto;">At the time the Purchaser was offered the Units, it was, and at the date hereof it is, an &#8220;accredited investor&#8221; as defined in each of Rule 501(a) under the Securities Act and the Accredited Investor Certification attached hereto as&#160;</font><font style="text-decoration:underline;color:#auto;">Annex B</font><font style="color:#auto;">. The Accredited Investor Certification&#160;is complete and accurate in all respects as of the date of this Subscription Agreement, and will continue to be complete and accurate as of the effectiveness date of any resale registration statement filed by the Company for the purpose of registering the securities contemplated by this Subscription Agreement (the &#8220;</font><font style="font-style:italic;color:#auto;font-weight:bold;">Resale Registration Statement</font><font style="color:#auto;">&#8221;); </font><font style="font-style:italic;color:#auto;">provided</font><font style="color:#auto;">, that the Purchaser shall be entitled to update such information by providing written notice thereof to the Company.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-weight:bold;font-size:18pt;margin-left:108pt;"></font><font style="color:#auto;">&#160;Prior to the execution of this Subscription Agreement, the Purchaser and the Purchaser&#8217;s attorney, accountant, purchaser representative and/or tax adviser, if any (collectively, the &#8220;</font><font style="font-style:italic;color:#auto;font-weight:bold;">Advisers</font><font style="color:#auto;">&#8221;), have received the Memorandum and all other documents requested by the Purchaser, have carefully reviewed such documents and the documents filed by the Company with the SEC, and understand the information contained therein.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="font-weight:bold;font-size:18pt;margin-left:108pt;"></font><font style="color:#auto;">Neither the SEC nor any state securities commission or other regulatory authority has approved the Units, the Shares, the Warrants, or the Warrant Shares, or passed upon or endorsed the merits of the offering of Units, or confirmed the accuracy or determined the adequacy of the Memorandum. The Memorandum has not been reviewed by any federal, state or other regulatory authority.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(f)</font><font style="font-weight:bold;font-size:18pt;margin-left:108pt;"></font><font style="color:#auto;">All documents, records, and books pertaining to the investment in the Units (including, without limitation, the Memorandum) have been made available for inspection by such Purchaser and its Advisers, if any.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="font-weight:bold;font-size:18pt;margin-left:108pt;"></font><font style="color:#auto;">The Purchaser and its Advisers, if any, have had a reasonable opportunity to ask questions of and receive answers from a person or persons acting on behalf of the Company concerning the Offering and the business and financial condition of the Company, and all such questions have been answered to the full satisfaction of the Purchaser and its Advisers, if any.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(h)</font><font style="font-weight:bold;font-size:18pt;margin-left:108pt;"></font><font style="color:#auto;">In evaluating the suitability of an investment in the Company, the Purchaser has not relied upon any representation or information (oral or written) other than as stated in or incorporated by reference into the Memorandum or any documents filed by the Company with the SEC.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-weight:bold;font-size:18pt;margin-left:108pt;"></font><font style="color:#auto;">The Purchaser is unaware of, is in no way relying on, and did not become aware of the Offering through or as a result of, any form of general solicitation or general advertising including, without limitation, any article, notice, advertisement or other communication published in any newspaper, magazine or similar media or broadcast over television, radio or the Internet (including, without limitation, the Company&#8217;s or SEC&#8217;s website, Internet &#8220;blogs,&#8221; bulletin boards, discussion groups and social networking sites) in connection with the Offering and is not subscribing for the Units and did not become aware of the Offering through or as a result of any seminar or meeting to which the Purchaser was invited by, or any solicitation of a subscription by, a person not previously known to the Purchaser in connection with investments in securities generally.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(j)</font><font style="font-weight:bold;font-size:18pt;margin-left:108pt;"></font><font style="color:#auto;">The Purchaser has taken no action that would give rise to any claim by any person for brokerage commissions, finders&#8217; fees or the like relating to this Subscription Agreement or the transactions contemplated hereby (other than the Commission and expenses to be paid or reimbursed by the Company to the Broker or as otherwise described in the Memorandum) and, in turn, to be paid to its selected dealers.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(k)</font><font style="font-weight:bold;font-size:18pt;margin-left:108pt;"></font><font style="color:#auto;">The Purchaser, together with its Advisers, if any, has such knowledge and experience in financial, tax, and business matters, and, in particular, investments in securities, so as to enable it to utilize the information made available to it in connection with the Offering to evaluate the merits and risks of an investment in the Units and the Company and to make an informed investment decision with respect thereto.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(l)</font><font style="font-weight:bold;font-size:18pt;margin-left:108pt;"></font><font style="color:#auto;">The Purchaser is not relying on the Company, the Broker, or any of their respective employees or agents with respect to the legal, tax, economic and related considerations of an investment in the Units, and the Purchaser has relied on the advice of, or has consulted with, only its own Advisers.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(m)</font><font style="font-weight:bold;font-size:18pt;margin-left:108pt;"></font><font style="color:#auto;">The Purchaser is acquiring the Units and, upon exercise of the Warrants, will acquire the Warrant Shares, as principal for its own account and not with a view to, or for distributing or reselling such securities or any part thereof in violation of the Securities Act or any applicable state securities laws; </font><font style="font-style:italic;color:#auto;">provided</font><font style="color:#auto;">, </font><font style="font-style:italic;color:#auto;">however</font><font style="color:#auto;">, that by making the representations herein, the Purchaser reserves the right, subject to the provisions of this Subscription Agreement and the Registration Rights Agreement, at all times to sell or otherwise dispose of all or any part of such securities pursuant to the Resale Registration Statement under the Securities Act or under an exemption from such registration and in compliance with applicable federal and state securities laws. The Purchaser is acquiring the Units hereunder in the ordinary course of its business. The Purchaser does not presently have any agreement, plan or understanding, directly or indirectly, with any person to distribute or effect any distribution of any of the Units, Shares, Warrants or Warrant Shares issuable upon exercise of the Warrants (or any securities which are derivatives thereof) to or through any person or entity; the Purchaser is not a registered broker-dealer under Section 15 of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="font-style:italic;color:#auto;font-weight:bold;">Exchange Act</font><font style="color:#auto;">&#8221;), or an entity engaged in a business that would require it to be so registered as a broker-dealer. Legends shall be placed on the securities included in the Units to the effect that they have not been registered under the Securities Act or applicable state securities laws. Appropriate notations will be made in the Company&#8217;s securities ledgers to the effect that the securities included in the Units have not been registered under the Securities Act or applicable state securities laws. Stop transfer instructions will be placed with the Company&#8217;s transfer agent on the securities. There can be no assurance that there will be any market for resale of the Units, the Shares, the Warrants, or the Warrant Shares nor can there be any assurance that such securities will be freely transferable at any time in the foreseeable future.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(n)</font><font style="font-weight:bold;font-size:18pt;margin-left:108pt;"></font><font style="color:#auto;">The Purchaser has adequate means of providing for such Purchaser&#8217;s current financial needs and foreseeable contingencies and has no need for liquidity of its investment in the Units for an indefinite period of time.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(o)</font><font style="font-weight:bold;font-size:18pt;margin-left:108pt;"></font><font style="color:#auto;">The Purchaser (i) if a natural person, represents that the Purchaser has reached the age of 21 and has full power and authority to execute and deliver this Subscription Agreement and any other agreements, documents or instruments delivered or required to be delivered together with or pursuant to this Subscription Agreement or in connection herewith (the &#8220;</font><font style="font-style:italic;color:#auto;font-weight:bold;">Subscription Documents</font><font style="color:#auto;">&#8221;) and to carry out the provisions hereof and thereof; (ii) if a corporation, partnership, or limited liability company or partnership, or association, joint stock company, trust, unincorporated organization or other entity, represents that such entity was not formed for the specific purpose of acquiring the Units, such entity is duly organized, validly existing and in good standing under the laws of the state of its organization, the consummation of the transactions contemplated hereby is authorized by, and will not result in a violation of state law or our charter or other organizational documents, such entity has full power and authority to execute and deliver the Subscription Documents and to carry out the provisions hereof and thereof and to purchase and hold the securities constituting the Units, the execution and delivery of the Subscription Documents have been duly authorized by all necessary action, the Subscription Documents to which it is a party have been duly executed and when delivered on behalf of such entity in accordance with the terms hereof, will constitute a legal, valid and binding obligation of such entity, enforceable against it in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, liquidation or similar laws relating to, or affecting generally the enforcement of, creditors&#8217; rights and remedies or by other equitable principles of general application; or (iii) if executing the Subscription Documents in a representative or fiduciary capacity, represents that it has full power and authority to execute and deliver the Subscription Documents in such capacity and on behalf of the subscribing individual, ward, partnership, trust, estate, corporation, or limited liability company, or other entity for whom the Purchaser is executing the Subscription Documents, and such individual, partnership, ward, trust, estate, corporation, or limited liability company, or other entity has full right and power to execute and deliver the Subscription Documents and all other related agreements or certificates and to carry out the provisions hereof and thereof and to purchase and hold the securities constituting the Units, and represents that the Subscription Documents constitute a legal, valid and binding obligation of such entity. The execution, delivery and performance of this Subscription Agreement and the Registration Rights Agreement, and the consummation by the Purchaser of the transactions contemplated hereby and thereby will not (i) result in a violation of the organizational documents of the Purchaser (except as to any Purchaser who is a natural person), (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Purchaser is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to the Purchaser, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations which would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of the Purchaser to perform its obligations hereunder.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(p)</font><font style="font-weight:bold;font-size:18pt;margin-left:108pt;"></font><font style="color:#auto;">The Purchaser and its Advisers, if any, have had the opportunity to obtain any additional information, to the extent the Company had such information in its possession or could acquire it without unreasonable effort or expense, necessary to verify the accuracy of the information contained in the Memorandum and all documents received or reviewed in connection with the purchase of the Units and have had the opportunity to have representatives of the Company provide them with such additional information regarding the terms and conditions of this particular investment and the financial condition, results of operations, and business of the Company deemed relevant by the Purchaser or the Advisers, if any, and all such requested information, to the extent the Company had such information in its possession or could acquire it without unreasonable effort or expense, has been provided to the full satisfaction of the Purchaser and the Advisers, if any.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(q)</font><font style="font-weight:bold;font-size:18pt;margin-left:108pt;"></font><font style="color:#auto;">Any information which the Purchaser has heretofore furnished or is furnishing herewith to the Company or the Broker is complete and accurate and may be relied upon by the Company and the Broker in determining the availability of an exemption from registration under federal and state securities laws in connection with the offering of securities as described in the Memorandum. The Purchaser further represents and warrants that it will notify and supply corrective information to the Company and the Broker immediately upon the occurrence of any change therein occurring prior to the Company&#8217;s issuance of the securities contained in the Units.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(r)</font><font style="font-weight:bold;font-size:18pt;margin-left:108pt;"></font><font style="color:#auto;">The Purchaser has significant prior investment experience, including investment in non-registered, high risk securities. The Purchaser has a sufficient net worth to sustain a loss of its entire investment in the Company in the event such a loss should occur. The Purchaser&#8217;s overall commitment to investments which are not readily marketable is not excessive in view of the Purchaser&#8217;s net worth and financial circumstances and the purchase of the Units will not cause such commitment to become excessive. The investment is a suitable one for the Purchaser.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(s)</font><font style="font-weight:bold;font-size:18pt;margin-left:108pt;"></font><font style="color:#auto;">The Purchaser is satisfied that the Purchaser has received adequate information with respect to all matters which it or its Advisers, if any, consider material to the Purchaser&#8217;s decision to make this investment.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(t)</font><font style="font-weight:bold;font-size:18pt;margin-left:108pt;"></font><font style="color:#auto;">The Purchaser acknowledges that any estimates or forward-looking statements or projections included in the Memorandum or in any documents filed with or furnished to the SEC by the Company were prepared by the Company in good faith but that the attainment of any such projections, estimates or forward-looking statements cannot be guaranteed by the Company and should not be relied upon.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(u)</font><font style="font-weight:bold;font-size:18pt;margin-left:108pt;"></font><font style="color:#auto;">No oral or written representations have been made, or oral or written information furnished, to the Purchaser or its Advisers, if any, in connection with the Offering which are in any way inconsistent with the information contained in the Memorandum or incorporated by reference in the Memorandum.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(v)</font><font style="font-weight:bold;font-size:18pt;margin-left:108pt;"></font><font style="color:#auto;">Within five (5) days after receipt of a request from the Company, the Purchaser will provide such information and deliver such documents as may reasonably be necessary to comply with any and all laws and ordinances to which the Company is subject.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(w)</font><font style="font-weight:bold;font-size:18pt;margin-left:108pt;"></font><font style="color:#auto;">NEITHER THE SECURITIES OFFERED HEREBY NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED WITH THE SEC OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT, AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(x)</font><font style="font-weight:bold;font-size:18pt;margin-left:108pt;"></font><font style="color:#auto;">The Purchaser acknowledges that none of the Units, the Shares, the Warrants, or the Warrant Shares issuable upon exercise of the Warrants have been recommended by any federal or state securities commission or regulatory authority. In making an investment decision, investors must rely on their own examination of the Company and the terms of the Offering, including the merits and risks involved. Furthermore, the foregoing authorities have not confirmed the accuracy or determined the adequacy of this Subscription Agreement or the Memorandum. Any representation to the contrary is a criminal offense. The Units, the Shares, the Warrants, and the Warrant Shares issuable upon exercise of the Warrants are subject to restrictions on transferability and resale and may not be transferred or resold except as permitted under the Securities Act, and the applicable state securities laws, pursuant to registration or exemption therefrom. The Purchaser is aware that it will be required to bear the financial risks of this investment for an indefinite period of time.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(y)</font><font style="font-weight:bold;font-size:18pt;margin-left:108pt;"></font><font style="color:#auto;font-weight:bold;">(For ERISA plans only)</font><font style="color:#auto;">&#160;The fiduciary of the ERISA plan (the &#8220;</font><font style="font-style:italic;color:#auto;font-weight:bold;">Plan</font><font style="color:#auto;">&#8221;) represents that such fiduciary has been informed of and understands the Company&#8217;s investment objectives, policies, and strategies, and that the decision to invest &#8220;plan assets&#8221; (as such term is defined in ERISA) in the Company is consistent with the provisions of ERISA that require diversification of plan assets and impose other fiduciary responsibilities. The Purchaser fiduciary or Plan (i) is responsible for the decision to invest in the Company; (ii) is independent of the Company or any of its affiliates; (iii) is qualified to make such investment decision; and (iv) in making such decision, the Purchaser fiduciary or Plan has not relied primarily on any advice or recommendation of the Company or any of its affiliates.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(z)</font><font style="font-weight:bold;font-size:18pt;margin-left:108pt;"></font><font style="color:#auto;font-weight:bold;">The Purchaser should check the U.S. Office of Foreign Assets Control website before making the following representations.</font><font style="color:#auto;"> The Purchaser represents that the amounts invested by it in the Offering were not and are not directly or indirectly derived from activities that contravene federal, state or international laws and regulations, including anti-money laundering laws and regulations. Federal regulations and Executive Orders administered by the U.S. Office of Foreign Assets Control (&#8220;</font><font style="font-style:italic;color:#auto;font-weight:bold;">OFAC</font><font style="color:#auto;">&#8221;) prohibit, among other things, the engagement in transactions with, and the provision of services to, certain foreign countries, territories, entities and individuals. The lists of OFAC prohibited countries, territories, persons and entities can be found on the OFAC website at http://www.treas.gov/ofac. In addition, the programs administered by OFAC (the &#8220;</font><font style="font-style:italic;color:#auto;font-weight:bold;">OFAC </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-style:italic;color:#auto;font-weight:bold;">Programs</font><font style="color:#auto;">&#8221;) prohibit dealing with individuals</font><sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup><font style="color:#000000;font-size:8pt;font-weight:bold;"><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup></font><font style="color:#auto;">&#160;or entities in certain countries regardless of whether such individuals or entities appear on the OFAC lists.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(aa)</font><font style="font-weight:bold;font-size:18pt;margin-left:108pt;"></font><font style="color:#auto;">None of: (1) the Purchaser; (2) any person controlling or controlled by the Purchaser; (3) if the Purchaser is a privately-held entity, any person having a beneficial interest in the Purchaser; or (4) any person for whom the Purchaser is acting as agent or nominee in connection with this investment is a country, territory, individual or entity named on an OFAC list, or a person or entity prohibited under the OFAC Programs. Please be advised that the Company may not accept any amounts from a prospective investor if such prospective investor cannot make the representation set forth in the preceding sentence. The Purchaser agrees to promptly notify the Company and the Broker should the Purchaser become aware of any change in the information set forth in these representations. The Purchaser understands and acknowledges that, by law, the Company may be obligated to &#8220;freeze the account&#8221; of the Purchaser, either by prohibiting additional subscriptions from the Purchaser, declining any redemption requests and/or segregating the assets in the account in compliance with governmental regulations, and the Broker may also be required to report such action and to disclose the Purchaser&#8217;s identity to OFAC. The Purchaser further acknowledges that the Company may, by written notice to the Purchaser, suspend the redemption rights, if any, of the Purchaser if the Company reasonably deems it necessary to do so to comply with anti-money laundering regulations applicable to the Company and the Broker or any of the Company&#8217;s other service providers. These individuals include specially designated nationals, specially designated narcotics traffickers and other parties subject to OFAC sanctions and embargo programs.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(bb)</font><font style="font-weight:bold;font-size:18pt;margin-left:108pt;"></font><font style="color:#auto;">None of: (1) the Purchaser; (2) any person controlling or controlled by the Purchaser; (3) if the Purchaser is a privately-held entity, any person having a beneficial interest in the Purchaser; or (4) any person for whom the Purchaser is acting as agent or nominee in connection with this investment is a senior foreign political figure,<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup></font><font style="color:#000000;font-size:8pt;font-weight:bold;"><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup></font><font style="color:#auto;">&#160;or any immediate family<sup style="font-size:85%;line-height:120%;vertical-align:top">3</sup></font><font style="color:#000000;font-size:8pt;font-weight:bold;"><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup></font><font style="color:#auto;">&#160;member or close associate<sup style="font-size:85%;line-height:120%;vertical-align:top">4</sup></font><font style="color:#000000;font-size:8pt;font-weight:bold;"><sup style="font-size:85%;line-height:120%;vertical-align:top"></sup></font><font style="color:#auto;">&#160;of a senior foreign political figure, as such terms are defined in the footnotes below.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(cc)</font><font style="font-weight:bold;font-size:18pt;margin-left:108pt;"></font><font style="color:#auto;">If the Purchaser is affiliated with a non-U.S. banking institution (a &#8220;</font><font style="font-style:italic;color:#auto;font-weight:bold;">Foreign Bank</font><font style="color:#auto;">&#8221;), or if the Purchaser receives deposits from, makes payments on behalf of, or handles other financial transactions related to a Foreign Bank, the Purchaser represents and warrants to the Company that: (1) the Foreign Bank has a fixed address, other than solely an electronic address, in a country in which the Foreign Bank is authorized to conduct banking activities; (2) the Foreign Bank maintains operating records related to its banking activities; (3) the Foreign Bank is subject to inspection by the banking authority that licensed the Foreign Bank to conduct banking activities; and (4) the Foreign Bank does not provide banking services to any other Foreign Bank that does not have a physical presence in any country and that is not a regulated affiliate.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(dd)</font><font style="font-weight:bold;font-size:18pt;margin-left:108pt;"></font><font style="color:#auto;">Other than with respect to the transactions contemplated herein, since the time that such Purchaser was first contacted by the Company, a broker or any other person regarding the transactions contemplated hereby, none of (i) the Purchaser, (ii) any affiliate of such Purchaser that (x) had knowledge of the transactions contemplated hereby, (y) has or shares discretion relating to such Purchaser&#8217;s investments or trading or information concerning such Purchaser&#8217;s investments, including in respect of the Units, and (z) is subject to such Purchaser&#8217;s review or input concerning such affiliate&#8217;s investments or trading (collectively, &#8220;</font><font style="font-style:italic;color:#auto;font-weight:bold;">Trading Affiliates</font><font style="color:#auto;">&#8221;) or (iii) any person acting on behalf of or pursuant to any understanding with such Purchaser or Trading Affiliate, has directly or indirectly effected or agreed to effect any purchases or sales of the securities of the Company (including, without limitation, any short sales involving the Company&#8217;s securities). Notwithstanding the foregoing, in the case of a Purchaser and/or Trading Affiliate that is, individually or collectively, a multi-managed investment bank or vehicle whereby separate portfolio managers manage separate portions of such Purchaser&#8217;s or Trading Affiliate&#8217;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser&#8217;s or Trading Affiliate&#8217;s assets, the representation set forth above shall apply only with respect to the portion of assets managed by the portfolio manager that has knowledge about the financing transaction contemplated by this Subscription Agreement. Other than to other persons party to this </font></p>
<div align="left"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:20%;"><tr><td style="width:20%;"></td></tr><tr><td valign="top"  style="border-bottom:Solid 1pt #000000;"><p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;text-indent:0pt;font-size:8pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;"> These individuals include specially designated nationals, specially designated narcotics traffickers and other parties subject to OFAC sanctions and embargo programs.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;"> A &#8220;senior foreign political figure&#8221; is defined as a senior official in the executive, legislative, administrative, military or judicial branches of a foreign government (whether elected or not), a senior official of a major foreign political party, or a senior executive of a foreign government-owned corporation. In addition, a &#8220;senior foreign political figure&#8221; includes any corporation, business or other entity that has been formed by, or for the benefit of, a senior foreign political figure.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">3</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;"> &#8220;Immediate family&#8221; of a senior foreign political figure typically includes the figure&#8217;s parents, siblings, spouse, children and in-laws.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:0%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">4</sup>&nbsp;</font></p></td>
<td valign="top" style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;"> A &#8220;close associate&#8221; of a senior foreign political figure is a person who is widely and publicly known to maintain an unusually close relationship with the senior foreign political figure, and includes a person who is in a position to conduct substantial domestic and international financial transactions on behalf of the senior foreign political figure.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#auto;">Subscription Agreement and prospective investors, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ee)</font><font style="font-weight:bold;font-size:18pt;margin-left:108pt;"></font><font style="color:#auto;">The Purchaser is aware that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of Common Stock and other activities with respect to the Common Stock held by the Purchaser.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ff)</font><font style="font-weight:bold;font-size:18pt;margin-left:108pt;"></font><font style="color:#auto;">The purchase by the Purchaser of the Shares and Warrants issuable to it at closing will not result in the Purchaser (individually or together with any other person with whom such Purchaser has identified, or will have identified, itself as part of a &#8220;group&#8221; in a public filing made with the SEC involving the Company&#8217;s securities) acquiring, or obtaining the right to acquire, in excess of 19.99% of the outstanding shares of Common Stock or the voting power of the Company on a post-transaction basis that assumes that such closing shall have occurred. The Purchaser does not presently intend to, alone or together with others, make a public filing with the SEC to disclose that it has (or that it together with such other persons has) acquired, or obtained the right to acquire, as a result of such closing (when added to any other securities of the Company that it or they then own or have the right to acquire), in excess of 19.99% of the outstanding shares of Common Stock or the voting power of the Company on a post-transaction basis that assumes that each closing shall have occurred.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(gg)</font><font style="font-weight:bold;font-size:18pt;margin-left:108pt;"></font><font style="color:#auto;">If the Purchaser is an officer of the Company or beneficial owner of 20% or more of the Company&#8217;s outstanding voting equity securities, such Purchaser does not qualify as a &#8220;bad actor&#8221; within the meaning of Rule 506(d) under the Securities Act.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.&#160;Company Representations and Warranties<font style="font-weight:normal;">. The Company represents and warrants to the Purchaser, except as and to the extent set forth in the publicly available reports, schedules, forms, statements and other documents filed by the Company with, or furnished by the Company to, the SEC (the &#8220;</font><font style="font-style:italic;">General Disclosure Package</font><font style="font-weight:normal;">&#8221;) as of the date hereof and as of each closing:</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#2F5496;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-weight:bold;font-size:18pt;margin-left:108pt;"></font><font style="color:#auto;">The Company is a corporation duly incorporated, validly existing and in good standing under the laws of the jurisdiction of its incorporation and has the requisite corporate power and authority to own its properties and to carry on its business as presently conducted. The Company is duly qualified as a foreign corporation to do business and is in good standing in each jurisdiction where the nature of the business conducted or property owned by it makes such qualification necessary except to the extent as would not reasonably be likely to have a material adverse effect.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-size:12pt;margin-left:108pt;color:#000000;"></font><font style="color:#000000;">&#160;The Company has all requisite corporate right, power and authority to enter into the Transaction Documents and to consummate the transactions contemplated hereby. All corporate action on the part of the Company, its directors and stockholders necessary for the: (i) authorization, execution, delivery and performance of the Transaction Documents by the Company; (ii) authorization, sale, issuance and delivery of the Units and securities comprising the Units contemplated hereby and the performance of the Company&#8217;s obligations hereunder; and (iii) authorization and reservation for issuance of the Warrant Shares issuable upon exercise of the Warrants, has been taken. When the Warrants are exercised in accordance with their terms, the Warrant Shares will be validly issued, fully paid and nonassessable. The issuance and sale of the securities contemplated hereby will not give rise to any preemptive rights or rights of first refusal on behalf of any person which have not been waived in connection with this Offering. The Company is not in default of any other obligations except as would not be reasonably expected to have a material adverse effect.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-size:12pt;margin-left:108pt;color:#000000;"></font><font style="color:#000000;">Assuming this Subscription Agreement has been duly and validly authorized, executed and delivered by the parties hereto and thereto other than the Company, this Subscription Agreement is duly authorized, executed and delivered by the Company and constitutes the legal, valid and binding obligations of the Company enforceable against the Company in accordance with its terms, except as such enforcement is limited by general equitable principles, or by bankruptcy, insolvency and other similar laws affecting the enforcement of creditors rights generally.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-size:12pt;margin-left:108pt;color:#000000;"></font><font style="color:#000000;">The execution, delivery and performance of this Subscription Agreement by the Company and the consummation by the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance of the Units and the Warrant Shares issuable upon exercise of the Warrants will not (i) result in a violation of the Certificate of Incorporation of the Company or other organizational documents of the Company, (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, acceleration or cancellation of, any agreement, </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">indenture, or instrument to which the Company is a party except as would not reasonably be expected to have a material adverse effect, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree applicable to the Company by which any property or asset of the Company is bound or affected except as would not reasonably be expected to have a material adverse effect.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="font-size:12pt;margin-left:108pt;color:#000000;"></font><font style="color:#000000;">The Company is not an &#8220;investment company&#8221; within the meaning of such term under the Investment Company Act of 1940, as amended, and the rules and regulations of the SEC promulgated thereunder.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="font-size:12pt;margin-left:108pt;color:#000000;"></font><font style="color:#000000;">Neither the Company nor any person participating on the Company&#8217;s behalf in the transactions contemplated hereby has conducted any &#8220;general solicitation,&#8221; as such term is defined in Regulation D, with respect to any of the securities being offered hereby.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="font-size:12pt;margin-left:108pt;color:#000000;"></font><font style="color:#000000;">The Company agrees to file a Form D with respect to the sale of the securities offered hereby under Regulation D of the rules and regulations promulgated under the Securities Act. The Company shall take such action as the Company shall reasonably determine is necessary to qualify the such securities for sale to the Purchaser pursuant to this Subscription Agreement under applicable securities or &#8220;blue sky&#8221; laws of the states of the United States (or to obtain an exemption from such qualification).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(h)</font><font style="font-size:12pt;margin-left:108pt;color:#000000;"></font><font style="color:#000000;">Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf, has directly or indirectly made any offers or sales in any security or solicited any offers to buy any security under circumstances that would require registration under the Securities Act of the issuance of the Units or Warrant Shares. The issuance of the Units and Warrant Shares will not be integrated with any other issuance of the Company&#8217;s securities (past, current or future) such that the offering of the Units or Warrant Shares would require registration under the Securities Act or would require stockholder approval pursuant to the Company&#8217;s Certificate of Incorporation or other organizational documents of the Company or the rules and regulations of Nasdaq.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-size:12pt;margin-left:108pt;color:#000000;"></font><font style="color:#000000;">The execution, delivery and performance of this Subscription Agreement by the Company will not (i) violate any law, treaty, rule or regulation applicable to or binding upon the Company or any of its properties or assets, or (ii) result in a breach of any contractual obligation to which the Company is a party or by which it or any of its properties or assets is bound that would reasonably be expected to have a material adverse effect on the ability of the Company to perform its obligations under this Subscription Agreement and the Transaction Documents.&#160;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8.&#160;Registration Rights<font style="font-weight:normal;">. Contemporaneously with the execution and delivery of this Subscription Agreement, the parties hereto are executing and delivering a Registration Rights Agreement pursuant to which, among other things, the Company will agree to provide certain registration rights with respect to the Shares and the Warrant Shares under the Securities Act and the rules and regulations promulgated thereunder and applicable state securities laws.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.&#160;Indemnification.<font style="font-weight:normal;">&#160;The Purchaser agrees to indemnify and hold harmless the Company, the Broker, and their respective officers, directors, members, stockholders, partners, representatives, employees, agents, control persons and affiliates from and against all losses, obligations, liabilities, claims, damages, contingencies, judgments, fines, penalties, charges, costs, fees and expenses whatsoever (including, but not limited to, any and all expenses incurred in investigating, preparing or defending against any action, claim, suit, inquiry, proceeding, investigation, appeal or litigation commenced or threatened by or before any court or governmental, administrative, or other regulatory agency or body or the SEC) (i) arising out of or based upon any untrue statement made by the Purchaser and contained in this Subscription Agreement; or (ii) arise out of or are based upon any breach by the Purchaser of any representation, warranty, or agreement made by Purchaser contained herein.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10.&#160;Irrevocability; Binding Effect.<font style="font-weight:normal;">&#160;The Purchaser hereby acknowledges and agrees that the subscription hereunder is irrevocable by the Purchaser, except as required by applicable law, and that this Subscription Agreement shall survive the death or disability of the Purchaser and shall be binding upon and inure to the benefit of the parties and their heirs, executors, administrators, successors, legal representatives, and permitted assigns. If the Purchaser is more than one person, the obligations of the Purchaser hereunder shall be joint and several and the agreements, representations, warranties, and acknowledgments herein shall be deemed to be made by and be binding upon each such person and such person&#8217;s heirs, executors, administrators, successors, legal representatives, and permitted assigns.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11.&#160;Immaterial Modifications to the Transaction Documents.&#160;<font style="font-weight:normal;">The Company may, at any time prior to the applicable closing, modify the Warrant and any other Transaction Document without first providing notice or obtaining prior consent of the Purchaser, if, and only if, such modification does not materially adversely affect such Purchaser&#8217;s rights.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.&#160;Notices.<font style="font-weight:normal;">&#160;Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered via e-mail transmission or other electronic transmission prior to 5:00 P.M., New York City time, on a trading day, (b) the next trading day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number specified in this Section 12 on a day that is not a trading day or later than 5:00 P.M., New York City time, on any trading day, (c) the trading day following the date of mailing, if sent by U.S. nationally recognized overnight courier service with next day delivery specified, or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as follows:</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:16.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to the Company to:</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:78.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Achieve Life Sciences, Inc.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1040 West Georgia Street, Suite 1030<br />Vancouver, British Columbia, Canada V6E 4H1</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: John Bencich</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email: jbencich@achievelifesciences.com</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:16.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:78.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:16.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With copies to:</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:78.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fenwick &amp; West LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1191 Second Avenue, Floor 10</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Seattle, Washington 98101</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Alan Smith, Amanda Rose and Chelsea Anderson</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E-mail: acsmith@fenwick.com, arose@fenwick.com and canderson@fenwick.com</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:16.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:78.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:16.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to the Purchaser to:</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:78.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The address set forth on the signature page hereto</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13.&#160;Assignability.<font style="font-weight:normal;">&#160;The provisions of this Subscription Agreement shall inure to the benefit of and be binding upon the parties and their successors and permitted assigns. This Subscription Agreement, or any rights or obligations hereunder, may not be assigned by the Company or the Purchaser without the prior written consent of the other party. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14.&#160;Applicable Law.&#160;<font style="font-weight:normal;">All questions concerning the construction, validity, enforcement and interpretation of this Subscription Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of Delaware, without regard to the principles of conflicts of law thereof.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">15.&#160;Arbitration.<font style="font-weight:normal;">&#160;The parties agree to submit all controversies to arbitration in accordance with the provisions set forth below and understand that: (a) arbitration is final and binding on the parties; (b) the parties are waiving their right to seek remedies in court, including the right to a jury trial; (c) pre-arbitration discovery is generally more limited and different from court proceedings; (d) the arbitrator&#8217;s award is not required to include factual findings or legal reasoning and any party&#8217;s right to appeal or to seek modification of rulings by arbitrators is strictly limited; and (e) the panel of arbitrators will typically include a minority of arbitrators who were or are affiliated with the securities industry.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;&#160;&#160;All controversies which may arise between the parties concerning this Subscription Agreement shall be determined by arbitration pursuant to the rules then pertaining to the American Arbitration Association in Seattle, Washington. The arbitration shall be governed by the Federal Arbitration Act, 9 U.S.C. Sec. 1-16, and the judgment upon the award rendered by the arbitrators may be entered by any court having jurisdiction thereof. Any notice of such arbitration or for the confirmation of any award in any arbitration shall be sufficient if given in accordance with the provisions of this Subscription Agreement. The parties agree that the determination of the arbitrators shall be binding and conclusive upon them.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">16.&#160;Blue Sky Qualification.<font style="font-weight:normal;">&#160;The purchase of Units under this Subscription Agreement is expressly conditioned upon the exemption from qualification of the offer and sale of the Units from applicable federal and state securities laws. The Company shall not be required to qualify this transaction under the securities laws of any jurisdiction, but to the extent the Company proceeds with the Offering and effects one or more closings, the </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">Company shall take such action as the Company shall reasonably determine is necessary to qualify the securities for sale to the Purchaser pursuant to this Subscription Agreement under applicable securities or &#8220;blue sky&#8221; laws of the states of the United States (or to obtain an exemption from such qualification).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">17.&#160;Use of Pronouns.<font style="font-weight:normal;">&#160;All pronouns and any variations thereof used herein shall be deemed to refer to the masculine, feminine, neuter, singular or plural as the identity of the person or persons referred to may require.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18.&#160;Confidentiality.<font style="font-weight:normal;">&#160;The Purchaser acknowledges and agrees that any information or data the Purchaser has acquired from or about the Company, not otherwise properly in the public domain, was received in confidence. The Purchaser agrees not to divulge, communicate or disclose, except as may be required by law or for the performance of this Subscription Agreement, or use to the detriment of the Company or for the benefit of any other person or persons, or misuse in any way, any confidential information of the Company, including any scientific, technical, trade or business secrets of the Company and any scientific, technical, trade or business materials that are treated by the Company as confidential or proprietary, including, but not limited to, ideas, discoveries, inventions, developments and improvements belonging to the Company and confidential information obtained by or given to the Company about or belonging to third parties.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">19. Counsel<font style="font-weight:normal;">. This Subscription Agreement and all the other Transaction Documents related to the Offering have been prepared by Fenwick &amp; West LLP, as counsel to the Company (&#8220;</font><font style="font-style:italic;">Counsel</font><font style="font-weight:normal;">&#8221;), after full disclosure of its representation of the Company and with the consent and direction of the Company and the Purchaser. The Purchaser acknowledges that he, she or it is fully aware of his, her or its right to the advice of counsel independent from that of the Company, that Counsel has advised the Purchaser of such right and disclosed to the Purchaser the risks in not seeking such independent advice, and that he, she or it understands the potentially adverse interests of the parties with respect to the Transaction Documents. The Purchaser further acknowledges that no representations have been made with respect to the tax or other consequences of the Transaction Documents to the Purchaser and that he, she or it has been advised of the importance of seeking independent counsel with respect to such consequences. By executing this Subscription Agreement, the Purchaser represents that he, she or it has, after being advised of the potential conflicts between the Purchaser and the Company with respect to the future consequences of the Transaction Documents, either consulted independent legal counsel or elected, notwithstanding the advisability of seeking such independent legal counsel, not to consult such independent legal counsel.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">20.&#160;Miscellaneous<font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;This Subscription Agreement (including the annexes hereto), together with the Transaction Documents (which are to be issued or executed at closing), constitutes the entire agreement between the Purchaser and the Company with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings, if any, relating to the subject matter hereof.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;The representations, warranties and covenants of the Company and the Purchaser made in this Subscription Agreement (including the annexes hereto) shall survive the execution and delivery hereof and delivery of the Units and Warrant Shares issuable upon exercise of the Warrants.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)&#160;Each of the parties hereto shall pay its own fees and expenses (including the fees of any attorneys, accountants, appraisers or others engaged by such party) in connection with this Subscription Agreement and the transactions contemplated hereby whether or not the transactions contemplated hereby are consummated.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)&#160;This Subscription Agreement may be executed in one or more counterparts each of which shall be deemed an original (including signatures sent by facsimile transmission or by email transmission of a PDF scanned document), but all of which shall together constitute one and the same instrument.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)&#160;Each provision of this Subscription Agreement shall be considered separable and, if for any reason any provision or provisions hereof are determined to be invalid or contrary to applicable law, such invalidity or illegality shall not impair the operation of or affect the remaining portions of this Subscription Agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)&#160;Paragraph titles are for descriptive purposes only and shall not control or alter the meaning of this Subscription Agreement as set forth in the text.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)&#160;The Purchaser understands and acknowledges that there may be multiple closings for this Offering.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)&#160;In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, the Purchaser and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations described in the foregoing sentence and hereby agree to waive in any action for specific performance of any such obligation (other than in connection with any action for a temporary restraining order) the defense that a remedy at law would be adequate.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:5.65pt;padding-Right:5.65pt;padding-Top:0pt;padding-Bottom:0pt;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[Signature Pages Follow]</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURE PAGE TO SUBSCRIPTION AGREEMENT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of the date first written above, Purchaser hereby elects to subscribe under the Subscription Agreement for a total of __________ Units at a price of $4.625 per Unit (NOTE: to be completed by Purchaser) and executes the Subscription Agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Purchaser is an INDIVIDUAL, and if purchased as JOINT TENANTS, as TENANTS IN COMMON, as COMMUNITY PROPERTY, or as an INDIVIDUAL RETIREMENT ACCOUNT:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.34%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%; border-bottom:solid 1.5pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.66%; border-bottom:solid 1.5pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%; border-bottom:solid 1.5pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.34%; border-bottom:solid 1.5pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Print Name(s)</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Social Security Number(s)</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.34%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%; border-bottom:solid 1.5pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.66%; border-bottom:solid 1.5pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%; border-bottom:solid 1.5pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.34%; border-bottom:solid 1.5pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Signature(s) of Subscriber(s)</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Signature</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.34%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%; border-bottom:solid 1.5pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.66%; border-bottom:solid 1.5pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%; border-bottom:solid 1.5pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.34%; border-bottom:solid 1.5pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Address</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.34%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%; border-bottom:solid 1.5pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.66%; border-bottom:solid 1.5pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:45.84%; border-bottom:solid 1.5pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.34%; border-bottom:solid 1.5pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Email Address</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.66%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Purchaser is a PARTNERSHIP, CORPORATION, LIMITED LIABILITY COMPANY or TRUST:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.34%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%; border-bottom:solid 1.5pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.66%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%; border-bottom:solid 1.5pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.34%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of Partnership,<br />Corporation, Limited<br />Liability Company or Trust</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Federal Taxpayer<br />Identification Number</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.34%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:2.56%; border-bottom:solid 1.5pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:43.2%; border-bottom:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.74%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%; border-bottom:solid 1.5pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.34%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:2.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:43.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">State of Organization</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:2.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:43.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.34%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%; border-bottom:solid 1.5pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.66%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%; border-bottom:solid 1.5pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.34%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Address</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.34%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%; border-bottom:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:1.66%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:45.84%; border-bottom:solid 1.5pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.34%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Email Address</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:45.84%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-weight:bold;">ACHIEVE LIFE SCIENCES, INC.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:5.64%; border-bottom:solid 1.5pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:34.76%; border-bottom:solid 1.5pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:59.6%; border-bottom:solid 1.5pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:5.64%; border-bottom:solid 1.5pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:34.76%; border-bottom:solid 1.5pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;John Bencich</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:59.6%; border-bottom:solid 1.5pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:5.64%; border-bottom:solid 1.5pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:34.76%; border-bottom:solid 1.5pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;Chief Executive Officer</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:59.6%; border-bottom:solid 1.5pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>achv-ex102_53.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
achv-ex102_53.htm
</title>
</head>
<!-- NG Converter v5.0.2.73 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 10.2</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">REGISTRATION RIGHTS AGREEMENT</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Registration Rights Agreement (this &#8220;<font style="font-weight:bold;font-style:italic;">Agreement</font>&#8221;) is made and entered into as of November 18, 2022 by and among Achieve Life Sciences, Inc., a Delaware corporation (the &#8220;<font style="font-weight:bold;font-style:italic;">Company</font>&#8221;), each of the persons who have executed counterpart signature pages hereto (each a &#8220;<font style="font-weight:bold;font-style:italic;">Purchaser</font>&#8221; and collectively, the &#8220;<font style="font-weight:bold;font-style:italic;">Purchasers</font>&#8221;).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">WHEREAS</font><font style="Background-color:#FFFFFF;font-weight:normal;">, the Company has agreed to enter into a registration rights agreement with each of the Purchasers who purchased Units pursuant to a subscription agreement of even date hereof (the &#8220;</font><font style="font-style:italic;Background-color:#FFFFFF;">Subscription Agreement</font><font style="Background-color:#FFFFFF;font-weight:normal;">&#8221;) in connection with the Offering, granting such Purchasers certain registration rights with respect to the Shares and Warrant Shares.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Subscription Agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.&#160;<font style="text-decoration:underline;">Definitions</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Affiliate</font>&#8221; means, with respect to any person, any other person which directly or indirectly controls, is controlled by, or is under common control with, such person.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-style:italic;">Commission</font>&#8221;&#160;<font style="font-weight:normal;">means the U.S. Securities and Exchange Commission.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-style:italic;">Common Stock</font>&#8221;&#160;<font style="font-weight:normal;">means the common stock of the Company, par value $0.001 per share.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-style:italic;">Effectiveness Date</font><font style="font-weight:normal;">&#8221; means, with respect to the Registration Statement required to be filed hereunder, the 180th&#160;calendar day following the final closing of the Offering;&#160;</font><font style="text-decoration:underline;font-weight:normal;">provided</font><font style="font-weight:normal;">,&#160;</font><font style="text-decoration:underline;font-weight:normal;">however</font><font style="font-weight:normal;">, that in the event the Company is notified by the Commission that one or more of the above Registration Statements will not be reviewed or is no longer subject to further review and comments, the Effectiveness Date as to such Registration Statement shall be the tenth (10th) Trading Day following the date on which the Company is so notified if such date precedes the dates otherwise required above, provided, further, if such Effectiveness Date falls on a day that is not a Trading Day, then the Effectiveness Date shall be the next succeeding Trading Day.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Exchange Act</font>&#8221; means the U.S. Securities Exchange Act of 1934, as amended, and the rules&#160;and regulations promulgated thereunder.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Filing Date</font>&#8221; means, with respect to the Registration Statement required hereunder, the 60th&#160;calendar day following the final closing of the Offering, provided, further, if such Filing Date falls on a Saturday, Sunday or other day that the Commission is closed for business, then the Filing Date shall be the next succeeding Trading Day on which the Commission is open for business.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">FINRA</font>&#8221; means the U.S. Financial Industry Regulatory Authority, Inc.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Holder</font>&#8221; or &#8220;<font style="font-weight:bold;font-style:italic;">Holders</font>&#8221; means the holder or holders, as the case may be, from time to time of Registrable Securities.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Prospectus</font>&#8221; means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information previously omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated by the Commission pursuant to the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and supplements to the Prospectus, including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Purchaser</font>&#8221; or &#8220;<font style="font-weight:bold;font-style:italic;">Purchasers</font>&#8221; has the meaning set forth in the Preamble.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Registrable Securities</font>&#8221; means, as of any date of determination: all of the (a) Shares, (b) Warrant Shares, and (c) any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect to the foregoing;&#160;<font style="text-decoration:underline;">provided</font>, that the Holder has completed and delivered to the Company a Selling Stockholder Questionnaire; and&#160;<font style="text-decoration:underline;">provided, further</font>, such Holder&#8217;s Shares and Warrant Shares shall cease to be Registrable Securities (and the Company shall not be required to maintain the effectiveness of any, or file another, Registration Statement hereunder with respect thereto) upon the earliest to occur of the following: (a) a Registration Statement with respect to the sale of such Registrable Securities is declared effective by the Commission under the Securities Act and such Registrable Securities have been disposed of by the Holder in accordance with such effective Registration Statement, (b) such Registrable Securities are sold in accordance with Rule 144 promulgated by the Commission pursuant to the Securities Act, or (c) such securities become eligible for resale by the Holder under Rule 144 without the requirement for the Company to be in compliance with the current public information requirement thereunder and without volume or manner-of-sale restrictions as set forth in a written opinion letter issued by counsel to the Company to such effect, addressed, delivered and acceptable to the Transfer Agent.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Registration Statement</font>&#8221; means any registration statement of the Company filed under the Securities Act that covers the resale of any of the Registrable Securities pursuant to Section 2(a), including amendments and supplements to any such registration statement, including pre- and post-effective amendments, all exhibits thereto, and all material incorporated by reference or deemed to be incorporated by reference in any such registration statement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Rule 415</font>&#8221; means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Rule 424</font>&#8221; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">SEC Guidance</font>&#8221; means (i) any publicly-available written or oral guidance of the Commission staff, or any comments, requirements or requests of the Commission staff and (ii) the Securities Act.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Securities Act</font>&#8221; means the U.S. Securities Act of 1933, as amended, and the rules&#160;and regulations promulgated thereunder.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Shares</font>&#8221; means the shares of Common Stock issued or issuable to the Purchasers pursuant to the Subscription Agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Trading Day</font>&#8221; means any day on which such national securities exchange, the OTC Pink Market, the OTCQB Market or such other securities market or quotation system, which at the time constitutes the principal securities market for the Common Stock, is open for general trading of securities.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Transfer Agent</font>&#8221; means American Stock Transfer &amp; Trust Company, LLC.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Warrants</font>&#8221; means the Warrants issued pursuant to the Subscription Agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;font-style:italic;">Warrant Shares</font>&#8221; means the shares of Common Stock issued or issuable upon exercise of the Warrants.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.&#160;Resale Registration.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;On or prior to the Filing Date, the Company shall prepare and file with the Commission a Registration Statement (which shall be on Form S-1 or if permitted in accordance with SEC Guidance and applicable rules, on Form S-3) covering the resale of all of the Registrable Securities that are not already registered on an existing and effective Registration Statement for an offering to be made on a continuous basis pursuant to Rule 415 or, if Rule 415 is not available for offers and sales of the Registrable Securities, by such other means of distribution of Registrable Securities as the Holders may reasonably specify. Subject to the terms of this Agreement, the Company shall use its reasonable best efforts to cause a Registration Statement filed under this Agreement to be declared </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effective by the Commission as soon as practical, but in any event no later than the Effectiveness Date, and shall use its reasonable best efforts to keep such Registration Statement continuously effective under the Securities Act (or file and keep continuously effective one or more replacement Registration Statements to register all Registrable Securities) until the earlier of (i) such time as all Registrable Securities covered by such Registration Statement have been publicly sold by Holders or (ii) the date that all Registrable Securities covered by such Registration Statement may be sold by non-affiliates without volume or manner-of-sale restrictions pursuant to Rule 144 and without the requirement for the Company to be in compliance with the current public information requirement under Rule 144, as determined by the counsel to the Company pursuant to a written opinion letter to such effect, addressed and reasonably acceptable to the Transfer Agent (the &#8220;</font><font style="font-weight:bold;font-style:italic;">Effectiveness Period</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;). The Company shall file a final Prospectus with the Commission as required by Rule 424 with respect to each Registration Statement.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;Notwithstanding the registration obligations set forth in Section 2(a), if the Commission informs the Company that all of the Registrable Securities cannot, as a result of the application of Rule 415, be registered for resale as a secondary offering on a single registration statement, the Company agrees to promptly (i) inform each of the Holders thereof and use its reasonable best efforts to file amendments to the Registration Statement as required by the Commission and/or (ii) withdraw the Registration Statement and file one or more new registration statements (together, the &#8220;<font style="font-weight:bold;font-style:italic;">New Registration Statement</font>&#8221;), in either case, covering the maximum number of Registrable Securities permitted to be registered by the Commission, on such other form available to register for resale the Registrable Securities as a secondary offering;&#160;<font style="text-decoration:underline;">provided</font>,&#160;<font style="text-decoration:underline;">however</font>, that prior to filing such amendment or New Registration Statement, the Company shall be obligated to use reasonable best efforts to advocate with the Commission for the registration of all of the Registrable Securities in accordance with the SEC Guidance.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)&#160;Notwithstanding any other provision of this Agreement, if the Commission or any SEC Guidance sets forth a limitation on the number of Registrable Securities permitted to be registered on a particular Registration Statement as a secondary offering, unless otherwise directed in writing by a Holder as to its Registrable Securities, the number of Registrable Securities to be registered on such Registration Statement will be reduced as follows: (i) first, by Registrable Securities not acquired pursuant to a Subscription Agreement; (ii) second, by Registrable Securities represented by Warrant Shares (applied, in the case that some shares may be registered, to such Holders on a pro rata basis based on the number of unregistered Warrant Shares held by such Holders); and (iii) third, by Registrable Securities represented by shares of Common Stock issued in the Offering (applied, in the case that if some of such shares of Common Stock may be registered, to the Holders on a pro rata basis based on the number of unregistered shares held by such Holders).</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)&#160;[RESERVED.]</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)&#160;Holder agrees to furnish to the Company a completed Selling Stockholder Questionnaire attached hereto as&#160;<font style="text-decoration:underline;">Exhibit A</font>&#160;on the date hereof. Prior to the first anticipated filing date of a Registration Statement for any registration under this Agreement, the Company will notify Holder of the information the Company requires from Holder other than the information contained in the Selling Stockholder Questionnaire, if any, which shall be completed and delivered to the Company promptly upon request and, in any event, no later than three (3) Trading Days prior to the applicable anticipated filing date. Holder further agrees that it shall not be entitled to be named as a selling stockholder in the Registration Statement or use a Prospectus for offers and resales of Registrable Securities at any time, unless Holder has returned to the Company a completed and signed Selling Stockholder Questionnaire and a response to any requests for further information in the time frame and as described in the previous sentence. Holder acknowledges and agrees that the information in the Selling Stockholder Questionnaire or request for further information as described in this Section 2(e) will be used by the Company in the preparation of the Registration Statement and hereby consents to the inclusion of such information in the Registration Statement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)&#160;In its sole discretion, the Company may undertake to register the Registrable Securities on Form&#160;S-3 after such form is available to the Company,&#160;<font style="font-style:italic;">provided</font>&#160;that the Company shall maintain the effectiveness of the Registration Statement then in effect until such time as a registration statement on Form&#160;S-3 covering the Registrable Securities has been declared by the Commission to be or otherwise becomes effective.&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.&#160;<font style="font-weight:bold;">Registration Procedures.</font>&#160;In connection with the Company&#8217;s registration obligations hereunder, the Company shall:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)(i) Prepare and file with the Commission such amendments, including post-effective amendments and supplements, to each Registration Statement and the Prospectus used in connection therewith as may be necessary to keep such Registration Statement continuously effective as to the applicable Registrable Securities for the Effectiveness Period; (ii) cause the related Prospectus to be amended or supplemented by any required Prospectus supplement (subject to the terms of this Agreement), and, as so supplemented or amended, to be filed pursuant to Rule 424; (iii) respond as promptly as reasonably practicable to any comments received from the Commission with respect to each Registration Statement or any amendment thereto; and (iv) during the Effectiveness Period, comply with the provisions of the Securities Act and the Exchange Act with respect to the disposition of all Registrable Securities covered by a Registration Statement until such time as all of such Registrable Securities shall have been disposed of (subject to the terms of this Agreement) in accordance with the intended methods of disposition by the Holders thereof as set forth in such Registration Statement as so amended or in such Prospectus as so supplemented; <font style="font-style:italic;">provided</font>, however, that each Holder shall be responsible for the delivery of the Prospectus to the Persons to whom such Holder sells any of the Shares or the Warrant Shares (including in accordance with Rule 172 under the Securities Act), and Holder agrees to dispose of Registrable Securities in compliance with applicable federal and state securities laws.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;Notify each Holder as promptly as reasonably practicable, but in no event later than seven (7) Trading Days after such event, (i) when the Registration Statement has become effective; (ii) of any request by the Commission or any other federal or state governmental authority for amendments or supplements to a Registration Statement or Prospectus or for additional information that pertains to the Holders as &#8220;Selling Stockholders&#8221; or the &#8220;Plan of Distribution&#8221;; (iii) of the issuance by the Commission or any other federal or state governmental authority of any stop order suspending the effectiveness of a Registration Statement covering any or all of the Registrable Securities or the initiation of any governmental action, litigation, hearing or other proceeding (&#8220;<font style="font-weight:bold;font-style:italic;">Proceedings</font>&#8221;) for that purpose; and (iv) of the receipt by the Company of any notification with respect to the suspension of the qualification or exemption from qualification of any of the Registrable Securities for sale in any jurisdiction, or the initiation of any Proceeding for such purpose.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)&#160;Use reasonable best efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order stopping or suspending the effectiveness of a Registration Statement; or (ii) any suspension of the qualification (or exemption from qualification) of any of the Registrable Securities for sale in any jurisdiction, as soon as practicable.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)&#160;Prior to any resale of Registrable Securities by a Holder, use its reasonable best efforts to register or qualify or cooperate with the selling Holders in connection with the registration or qualification (or exemption from the Registration or qualification) of such Registrable Securities for the resale by the Holder under the securities or Blue Sky laws of such jurisdictions within the United States as any Holder reasonably requests in writing, to keep each registration or qualification (or exemption therefrom) effective during the Effectiveness Period and to do any and all other acts or things reasonably necessary to enable the disposition in such jurisdictions of the Registrable Securities covered by each Registration Statement; <font style="font-style:italic;">provided</font>, that the Company shall not be required to qualify generally to do business in any jurisdiction where it is not then so qualified, subject the Company to any material tax in any such jurisdiction where it is not then so subject or file a general consent to service of process in any such jurisdiction.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)&#160;If requested by a Holder, cooperate with such Holder to facilitate the preparation and delivery of certificates or book entry statements representing Registrable Securities to be delivered to a transferee pursuant to a Registration Statement, which certificates or book entry statements shall be free, to the extent permitted by the Subscription Agreement and under law, of all restrictive legends, and to enable such Registrable Securities to be in such denominations and registered in such names as any such Holder may reasonably request.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)&#160;<font style="font-size:12pt;"> </font>Use its best efforts to promptly regain compliance with the listing and listing maintenance requirements of The Nasdaq Stock Market LLC applicable to it for the continued trading of its shares of Common Stock on Nasdaq.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)&#160;[RESERVED.]</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)&#160;[RESERVED.]</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)&#160;The Company may require each selling Holder to furnish to the Company a certified statement as to (i)&#160;the number of shares of Common Stock beneficially owned by such Holder and any Affiliate thereof, (ii)&#160;any FINRA affiliations, (iii)&#160;any natural persons who have the power to vote or dispose of the Common Stock and (iv)&#160;any other information as may be requested by the Commission, FINRA or any state securities commission.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.&#160;<font style="font-weight:bold;">Registration Expenses</font>. All fees and expenses incident to the Company&#8217;s performance of or compliance with this Agreement by the Company shall be borne by the Company whether or not any Registrable Securities are sold pursuant to a Registration Statement. In no event however shall the Company be responsible for any underwriting, broker or similar commissions of any Holder or any legal fees or other costs of the Holders except for the Fees and expenses incurred in connection with the Offering.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.&#160;Indemnification.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;<font style="font-weight:bold;">Indemnification by the Company</font>. The Company shall, notwithstanding any termination of this Agreement, indemnify and hold harmless each Holder, the officers, directors, members, partners, agents, brokers (including brokers who offer and sell Registrable Securities as principal as a result of a pledge or any failure to perform under a margin call of Common Stock), investment advisors and employees of each of them, each Person who controls any such Holder (within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act) and the officers, directors, members, stockholders, partners, agents and employees of each such controlling Person, to the fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including, without limitation, reasonable attorneys&#8217; fees) and expenses (collectively, &#8220;<font style="font-weight:bold;">Losses</font>&#8221;), as incurred, arising out of or based upon (1) any untrue statement of a material fact contained in any Registration Statement, any Prospectus or any form of prospectus or in any amendment or supplement thereto, preliminary prospectus, free writing prospectus (as defined in Rule 405 promulgated under the Securities Act), or arising out of or relating to any omission to state a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading or (2) any violation by the Company of the Securities Act, the Exchange Act or any state securities law, or any rule or regulation thereunder, in connection with the performance of its obligations under this Agreement, except to the extent that (i) such untrue statements or omissions are based solely upon information regarding such Holder furnished in writing to the Company by such Holder for use therein, or to the extent that such information relates to such Holder or such Holder&#8217;s proposed method of distribution of Registrable Securities and was reviewed and approved in writing by such Holder for use in a Registration Statement, such Prospectus, preliminary prospectus, free writing prospectus, or in any amendment or supplement thereto (it being understood that each Holder has approved the contents of the Selling Stockholder Questionnaire for this purpose), (ii) the use by a Holder of an outdated, defective or otherwise unavailable Prospectus after the Company has notified the Holder in writing that the Prospectus is outdated, defective or otherwise unavailable for use by such Holder or an updated Prospectus becomes available on the EDGAR filing system or (iii) to the extent that any such Losses arise out of the Holder&#8217;s (or any other Indemnified Party&#8217;s) failure to send or give a copy of the Prospectus or supplement (as then amended or supplemented), if required, pursuant to Rule 172 under the Securities Act (or any successor rule) to the Persons asserting an untrue statement or alleged untrue statement or omission or alleged omission at or prior to the written confirmation of the sale of the Registrable Securities to such Person if such statement or omission was corrected in such Prospectus or supplement. The Company shall notify the Holders of the institution, threat or assertion of any governmental action, litigation, hearing or other proceeding arising from or in connection with the transactions contemplated by this Agreement of which the Company is aware.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;<font style="font-weight:bold;">Indemnification by Holders</font>. Each Holder shall, severally and not jointly, indemnify and hold harmless the Company, its directors, officers, agents, stockholders, Affiliates, and employees, each Person who controls the Company (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, partners, members, managers, stockholders, agents or employees of such controlling Persons, to the fullest extent permitted by applicable law, from and against all Losses, as incurred, to the extent arising out of or based upon: (x) such Holder&#8217;s failure to comply with any applicable prospectus delivery requirements of the Securities Act through no fault of the Company or (y) any untrue or alleged untrue statement of a material fact contained in any Registration Statement, any Prospectus, preliminary prospectus, free writing prospectus, or in any amendment or supplement thereto, or arising out of or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any Prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading (i) to the extent that </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such untrue statement or omission is based upon information furnished by such Holder to the Company for inclusion in such Registration Statement or such Prospectus or (ii) to the extent that such information relates to such Holder&#8217;s proposed method of distribution of Registrable Securities and was reviewed and approved by such Holder for use in a Registration Statement (it being understood that the Holder has approved the contents of the Selling Stockholder Questionnaire for this purpose), such Prospectus, preliminary prospectus, free writing prospectus, or in any amendment or supplement thereto or (iii) to the extent related to the use by such Holder of an outdated, defective or otherwise unavailable Prospectus after the Company has notified the Holder that the Prospectus is outdated, defective or otherwise unavailable for use by such Holder or an updated Prospectus becomes available on the EDGAR filing system; provided that the total amounts payable in indemnity by such Holder under this Section 5(b) shall not exceed the net proceeds received by such Holder in the registered offering out of which such Losses arise.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)&#160;<font style="font-weight:bold;">Conduct of Indemnification Proceedings</font>. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i) If any Proceeding shall be brought or asserted against any Person entitled to indemnity hereunder (an &#8220;<font style="font-weight:bold;font-style:italic;">Indemnified Party</font>&#8221;), such Indemnified Party shall promptly notify the Person from whom indemnity is sought (the &#8220;<font style="font-weight:bold;font-style:italic;">Indemnifying Party</font>&#8221;) in writing, and the Indemnifying Party shall have the right to assume the defense thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all reasonable fees and expenses incurred in connection with defense thereof; provided, that the failure of any Indemnified Party to give such notice shall not relieve the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only) to the extent that it shall be finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) that such failure shall have materially and adversely prejudiced the Indemnifying Party.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)&#160;An Indemnified Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying Party has agreed in writing to pay such fees and expenses, (2) the Indemnifying Party shall have failed promptly to assume the defense of such Proceeding and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding, or (3) the named parties to any such Proceeding (including any impleaded parties) include both such Indemnified Party and the Indemnifying Party, and such Indemnified Party shall have been advised by counsel that a material conflict of interest exists if the same counsel were to represent such Indemnified Party and the Indemnifying Party (in which case, if such Indemnified Party notifies the Indemnifying Party in writing that it elects to employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not have the right to assume the defense thereof and the reasonable fees and expenses of no more than one separate counsel shall be at the expense of the Indemnifying Party). The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected without its written consent, which consent shall not be unreasonably withheld, delayed or conditioned. No Indemnifying Party shall, without the prior written consent of the Indemnified Party, effect any settlement of any pending Proceeding in respect of which any Indemnified Party is a party, unless such settlement includes an unconditional release of such Indemnified Party from all liability on claims that are the subject matter of such Proceeding.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)&#160;Subject to the terms of this Agreement, all reasonable fees and expenses of the Indemnified Party (including reasonable fees and expenses to the extent incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this Section) shall be paid to the Indemnified Party, as incurred, within ten (10) Trading Days of written notice thereof to the Indemnifying Party; provided, that, the Indemnified Party shall promptly reimburse the Indemnifying Party for that portion of such fees and expenses applicable to such actions for which such Indemnified Party is finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) not to be entitled to indemnification hereunder.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)&#160;<font style="font-weight:bold;">Contribution</font>. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i) If a claim for indemnification under Section 5(a) or 5(b) is unavailable to an Indemnified Party or insufficient to hold an Indemnified Party harmless for any Losses, then each Indemnifying Party, in lieu of indemnifying such Indemnified Party, shall contribute to the amount paid or payable by such Indemnified Party as a result of such Losses, in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party in connection with the actions, statements or omissions that resulted in such Losses as well as any </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other relevant equitable considerations. The relative fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission of a material fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties&#8217; relative intent, knowledge, access to information and opportunity to correct or prevent such action, statement or omission. The amount paid or payable by a party as a result of any Losses shall be deemed to include, subject to the limitations set forth in this Agreement, any reasonable attorneys&#8217; or other reasonable fees or expenses incurred by such party in connection with any Proceeding to the extent such party would have been indemnified for such fees or expenses if the indemnification provided for in this Section was available to such party in accordance with its terms.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)&#160;The parties hereto agree that it would not be just and equitable if contribution pursuant to this Section 5(d) were determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to in the immediately preceding paragraph. Notwithstanding the provisions of this Section 5(d), no contribution will be made under circumstances where the maker of such contribution would not have been required to indemnify the Indemnified Party under the fault standards set forth in this&#160;Section 5. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)&#160;The indemnity and contribution agreements contained in this Section are in addition to any liability that the Indemnifying Parties may have to the Indemnified Parties and are not in diminution or limitation of the indemnification provisions under the Subscription Agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.&#160;<font style="font-weight:bold;">Miscellaneous</font>.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)&#160;<font style="font-weight:bold;">Remedies</font>. In the event of a breach by the Company or by Holder of any of its obligations under this Agreement, Holder or the Company, as the case may be, in addition to being entitled to exercise all rights granted by law and under this Agreement, including recovery of damages, shall be entitled to specific performance of its rights under this Agreement. Each of the Company and Holder agrees that monetary damages would not provide adequate compensation for any Losses incurred by reason of a breach by it of any of the provisions of this Agreement and hereby further agrees that, in the event of any action for specific performance in respect of such breach, it shall not assert or shall waive the defense that a remedy at law would be adequate.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)&#160;<font style="font-weight:bold;">Compliance</font>. Holder covenants and agrees that it will comply with the prospectus delivery requirements of the Securities Act as applicable to it (unless an exemption therefrom is available) in connection with sales of Registrable Securities pursuant to a Registration Statement and shall sell the Registrable Securities only in accordance with a method of distribution described in a Registration Statement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)&#160;<font style="font-weight:bold;">Discontinued Disposition</font>. By its acquisition of Registrable Securities, Holder agrees that, upon receipt of a notice from the Company of the occurrence of any event that makes the Registration Statement outdated, defective or otherwise unavailable, Holder will forthwith discontinue disposition of such Registrable Securities under a Registration Statement until it is advised in writing by the Company or an agent of the Company that the use of the applicable Prospectus (as it may have been supplemented or amended) may be resumed. The Company will use its reasonable best efforts to ensure that the use of the Prospectus may be resumed as promptly as is practicable, and shall advise Holder thereof as promptly as practicable.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)&#160;<font style="font-weight:bold;">Piggy-Back Registrations</font>. If, at any time during the Effectiveness Period and after the Effectiveness Date, there is not an effective Registration Statement covering all of the Registrable Securities and the Company shall determine to prepare and file with the Commission a registration statement relating to an offering for its own account or the account of others under the Securities Act of any of its equity securities, other than on Form S-4 or Form S-8 (each as promulgated under the Securities Act) or their then equivalents relating to equity securities to be issued solely in connection with any acquisition of any entity or business or equity securities issuable in connection with the Company&#8217;s incentive, stock option or other employee benefit plans, then the Company shall deliver to the Holder a written notice of such determination and, if within five (5) Trading Days after the date of the delivery of such notice, Holder shall so request in writing, the Company shall include in such registration statement all or any part of such Registrable Securities such Holder requests to be registered; provided, however, that the Company shall </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not be required to register any Registrable Securities pursuant to this Section 6(d) that are the subject of an existing effective Registration Statement. The registration of the Registrable Securities pursuant to this Section 6(d) shall not be considered the satisfaction of the requirements of the Company pursuant to Sections 2 and 3 of this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)&#160;<font style="font-weight:bold;">Addresses and Notices.</font>&#160;Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered via e-mail transmission or facsimile (provided the sender receives a machine-generated confirmation of successful transmission) at the facsimile number specified in this Section prior to 5:00 P.M., New York City time, on a business day, (b) the next business day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number specified in this Section on a day that is not a business day or later than 5:00 P.M., New York City time, on any business day, (c) the business day following the date of mailing, if sent by U.S. nationally recognized overnight courier service with next day delivery specified, or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as follows:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td rowspan="2" valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td rowspan="2" valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to the Company to:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:74.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Achieve Life Sciences, Inc.</p></td>
</tr>
<tr style="height:49.05pt;">
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:74.04%;">
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1040 West Georgia Street, Suite 1030</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vancouver, British Columbia, Canada V6E 4H1</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: John Bencich</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email: jbencich@achievelifesciences.com</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:74.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td rowspan="2" valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td rowspan="2" valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With copies to:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:74.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fenwick &amp; West LLP</p></td>
</tr>
<tr style="height:53.55pt;">
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:74.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1191 Second Avenue, Floor 10</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Seattle, Washington 98101</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Alan Smith, Amanda Rose and Chelsea Anderson</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E-mail: acsmith@fenwick.com, arose@fenwick.com, canderson@fenwick.com</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:74.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to a Holder:</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:74.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As set forth on their signature page hereto</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)&#160;<font style="font-weight:bold;">Titles and Captions.</font>&#160;All Article and Section titles or captions in this Agreement are for convenience only. They shall not be deemed part of this Agreement and do not in any way define, limit, extend or describe the scope or intent of any provisions hereof.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)&#160;<font style="font-weight:bold;">Assignability.&#160;</font>This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of each of the parties and shall inure to the benefit of Holder. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. The Company may not assign its rights (except by merger or in connection with another entity acquiring all or substantially all of the Company&#8217;s assets) or obligations hereunder without the prior written consent of the Holders holding no less than two-thirds of the then outstanding Registrable Securities. A Holder may assign its respective rights hereunder; <font style="font-style:italic;">provided</font> in each case that (i) the Holder agrees in writing with the transferee or assignee to assign such rights and related obligations under this Agreement, and for the transferee or assignee to assume such obligations, and a copy of such agreement is furnished to the Company within a reasonable time after such assignment; (ii) the Company is, within a reasonable time after such transfer or assignment, furnished with written notice of the name and address of such transferee or assignee and the securities with respect to which such registration rights are being transferred or assigned; (iii) at or before the time the Company received the written notice contemplated by clause (ii) of this sentence, the transferee or assignee agrees in writing with the Company to be bound by all of the provisions contained herein; and (iv) the transferee is an &#8220;accredited investor,&#8221; as that term is defined in Rule 501 of Regulation D.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)&#160;<font style="font-weight:bold;">Applicable Law.</font>&#160;All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be determined in accordance with the provisions of the Subscription Agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)&#160;<font style="font-weight:bold;">Amendments and Waivers.</font>&#160;The provisions of this Agreement, including the provisions of this sentence, may not be amended, modified or supplemented, or waived unless the same shall be in writing and signed by the Company and Holders holding no less than a majority of the then outstanding Registrable Securities, in which case such amendment, modification, supplement or waiver shall be binding on all Holders, provided that any party may give a waiver as to itself.&#160; Notwithstanding the foregoing,&#160; a waiver or consent to depart from the provisions hereof with respect to a matter that relates exclusively to the rights of Holders and that does not directly or indirectly affect the rights of other Holders may be given by Holders of all of the Registrable Securities to which such waiver or consent relates;&#160;provided,&#160;however, that the provisions of this sentence may not be amended, modified, or supplemented except in accordance with the provisions of the immediately preceding sentence.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(j)&#160;<font style="font-weight:bold;">Counterparts.&#160;</font>This Agreement may be executed in counterparts, each of which will be deemed to be an original copy of this Agreement and all of which, when taken together, will be deemed to constitute one and the same agreement. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a &#8220;.pdf&#8221; format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &#8220;.pdf&#8221; signature page were an original thereof.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(k)&#160;<font style="font-weight:bold;">Severability.&#160;</font>If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their good faith reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction.&#160; It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;">IN WITNESS WHEREOF<font style="font-variant: normal;">, the parties have executed this Agreement as of the date first written above.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACHIEVE LIFE SCIENCES, INC.</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:35.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:59%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:5.56%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:35.44%; border-bottom:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:35.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John Bencich</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:59%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:35.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;">IN WITNESS WHEREOF<font style="font-variant: normal;">, the parties have executed this Agreement as of the date first written above.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:59.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NAME OF HOLDER</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:59.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:32.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:59.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AUTHORIZED SIGNATORY</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:59.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:32.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:59.18%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:8.28%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:32.56%; border-bottom:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:59.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:32.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:59.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:32.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:59.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:32.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:59.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ADDRESS</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:32.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:59.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:32.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:59.18%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:8.28%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c/o:</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:32.56%; border-bottom:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:59.18%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:8.28%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Street:</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:32.56%; border-bottom:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:59.18%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:8.28%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">City/State/Zip:</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:32.56%; border-bottom:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:59.18%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:8.28%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention:</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:32.56%; border-bottom:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:59.18%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:8.28%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tel:</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:32.56%; border-bottom:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:59.18%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:8.28%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fax:</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:32.56%; border-bottom:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:59.18%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:8.28%; border-bottom:solid 1.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email:</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:32.56%; border-bottom:solid 1.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit A<br /><br />Selling Stockholder Notice and Questionnaire</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The undersigned holder of shares of the common stock, par value $0.001 per share (the &#8220;<font style="font-weight:bold;">Common Stock</font>&#8221;), or securities exercisable for shares of the Common Stock&nbsp;&nbsp;(the &#8220;<font style="font-weight:bold;">Registrable Securities</font>&#8221;) of Achieve Life Sciences, a Delaware corporation (the &#8220;<font style="font-weight:bold;">Company</font>&#8221;), issued pursuant to a certain Subscription Agreement (the &#8220;<font style="font-weight:bold;">Subscription Agreement</font>&#8221;), understands that the Company intends to file with the Securities and Exchange Commission (the &#8220;<font style="font-weight:bold;">Commission</font>&#8221;) a registration statement (the &#8220;<font style="font-weight:bold;">Registration Statement</font>&#8221;) for the registration and resale under Rule 415 of the Securities Act of 1933, as amended (the &#8220;<font style="font-weight:bold;">Securities Act</font>&#8221;), of the Registrable Securities, in accordance with the terms of the Subscription Agreement. A copy of the Subscription Agreement is available from the Company upon request at the address set forth below. All capitalized terms not otherwise defined herein shall have the meanings ascribed thereto in the Subscription Agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to sell or otherwise dispose of any Registrable Securities pursuant to the Registration Statement, a holder of Registrable Securities generally will be required to be named as a selling stockholder in the related prospectus or a supplement thereto (as so supplemented, the &#8220;<font style="font-weight:bold;">Prospectus</font>&#8221;), deliver the Prospectus to purchasers of Registrable Securities (including pursuant to Rule&#160;172 under the Securities Act) and be bound by the provisions of the Subscription Agreement (including certain indemnification provisions, as described below).&#160; Holders must complete and deliver this Notice and Questionnaire in order to be named as selling stockholders in the Prospectus. <font style="font-weight:bold;">Holders of Registrable Securities who do not complete, execute and return this Notice and Questionnaire within three (3)&#160;Trading Days following the date of the Subscription Agreement (1)&#160;will not be named as selling stockholders in the Registration Statement or the Prospectus and (2)&#160;may not use the Prospectus for resales of Registrable Securities.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain legal consequences arise from being named as a selling stockholder in the Registration Statement and the related prospectus. Accordingly, holders of Registrable Securities are advised to consult their own securities law counsel regarding the consequences of being named or not being named as a selling stockholder in the Registration Statement and the related prospectus.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTICE</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The undersigned holder (the &#8220;<font style="font-weight:bold;">Selling Stockholder</font>&#8221;) of Registrable Securities hereby gives notice to the Company of its intention to sell or otherwise dispose of Registrable Securities owned by it and listed below in Item (3), unless otherwise specified in Item (3), pursuant to the Registration Statement.&#160; The undersigned, by signing and returning this Notice and Questionnaire, understands and agrees that it will be bound by the terms and conditions of this Notice and Questionnaire and the Subscription Agreement.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The undersigned hereby provides the following information to the Company and represents and warrants that such information is accurate and complete.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SELLING STOCKHOLDER<br />QUESTIONNAIRE</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:96.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:93.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Full Legal Name of Selling Stockholder</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:93.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:93.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Full Legal Name of Registered Holder (if not the same as (a) above) through which Registrable Securities are held:</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:93.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:93.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Full Legal Name of Natural Control Person(s) (which means a natural person who directly or indirectly alone or with others has power to vote or dispose of the securities covered by this Questionnaire):</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:93.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:auto; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2. Address for Notices to Selling Stockholder.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />Telephone: ______________________________________________________________________</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email: ____________________________________________________________________________</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contact Person: ___________________________________________________________________</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.88%;text-indent:-2.88%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3. Beneficial Ownership of Registrable Securities Issuable Pursuant to the Subscription Agreement:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.88%;text-indent:-2.88%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:0.53%;"></td>
<td style="width:2.5%;"></td>
<td style="width:96.97%;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Type and Number of Registrable Securities beneficially owned and issued pursuant to the Subscription Agreement:</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Number of shares of Common Stock to be registered pursuant to this Notice for resale:</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.88%;text-indent:-2.88%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4. Broker-Dealer Status.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:23.86%;">
<tr>
<td style="width:0.06%;"></td>
<td style="width:2.37%;"></td>
<td style="width:21.42%;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Are you a broker-dealer?</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes <font style="font-family:Segoe UI Symbol;">&#9744;</font>&#160;No <font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:0.06%;"></td>
<td style="width:2.5%;"></td>
<td style="width:97.44%;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If &#8220;yes&#8221; to Section 4(a), did you receive your Registrable Securities as compensation for investment banking services to the Company?</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes <font style="font-family:Segoe UI Symbol;">&#9744;</font>&#160;No <font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note:</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:93.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If &#8220;no&#8221; to Section 4(b), the Commission&#8217;s staff has indicated that you should be identified as an underwriter in the Registration Statement.</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:93.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Are you an affiliate of a broker-dealer?</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes <font style="font-family:Segoe UI Symbol;">&#9744;</font>&#160;No <font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note: If yes, provide a narrative explanation below:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:93.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If you are an affiliate of a broker-dealer, do you certify that you purchased the Registrable Securities in the ordinary course of business, and at the time of the purchase of the Registrable Securities to be resold, you had no agreements or understandings, directly or indirectly, with any person to distribute the Registrable Securities?</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes <font style="font-family:Segoe UI Symbol;">&#9744;</font>&#160;No <font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Note:</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:93.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If &#8220;no&#8221; to Section 4(d), the Commission&#8217;s staff has indicated that you should be identified as an underwriter in the Registration Statement.</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5. Beneficial Ownership of Other Securities of the Company Owned by the Selling Stockholder.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Except as set forth below in this Item 5, the undersigned is not the beneficial or registered owner of any securities of the Company other than the Registrable Securities listed above in Item 3.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:93.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Type and Amount of other securities beneficially owned by the Selling Stockholder:</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:93.34%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.34%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:93.34%; border-bottom:solid 1pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6. Relationships with the Company.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-15.38%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Except as set forth below, neither the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners of 5% of more of the equity securities of the undersigned) has held any position or office or has had any other material relationship with the Company (or its predecessors or affiliates) during the past three years.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State any exceptions here:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.34%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:5.65pt;padding-Right:5.65pt;padding-Top:0pt;padding-Bottom:0pt;width:96.66%; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:5.65pt;padding-Right:5.65pt;padding-Top:0pt;padding-Bottom:0pt;width:96.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.34%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:5.65pt;padding-Right:5.65pt;padding-Top:0pt;padding-Bottom:0pt;width:96.66%; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7. Plan of Distribution.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The undersigned has reviewed the form of Plan of Distribution to be included in the Prospectus, and hereby confirms that, except as set forth below, the information contained therein regarding the undersigned and its plan of distribution is correct and complete, and the undersigned acknowledges and agrees that it will sell the Registrable Securities in accordance with the Plan of Distribution.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State any exceptions here:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.38%;text-indent:-7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.34%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:5.65pt;padding-Right:5.65pt;padding-Top:0pt;padding-Bottom:0pt;width:96.66%; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:5.65pt;padding-Right:5.65pt;padding-Top:0pt;padding-Bottom:0pt;width:96.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:3.34%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:5.65pt;padding-Right:5.65pt;padding-Top:0pt;padding-Bottom:0pt;width:96.66%; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The undersigned agrees to promptly notify the Company of any inaccuracies or changes in the information provided herein that may occur subsequent to the date hereof and prior to the effective date of the applicable Registration Statement. All notices hereunder and pursuant to the Agreement shall be made at the address set forth below. In the absence of any such notification, the Company shall be entitled to continue to rely on the accuracy of the information in this Notice and Questionnaire.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By signing below, the undersigned consents to the disclosure of the information contained herein in its answers to Items 1 through 7 and the inclusion of such information in the Registration Statement and the related </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">prospectus and any amendments or supplements thereto. The undersigned understands that such information will be relied upon by the Company in connection with the preparation or amendment of the Registration Statement and the related prospectus and any amendments or supplements thereto.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By signing below, the undersigned acknowledges that it understands its obligation to comply, and agrees that it will comply, with the provisions of the Exchange Act and the rules&#160;and regulations thereunder, particularly Regulation M&#160;in connection with any offering of Registrable Securities pursuant to the Registration Statement.&#160; The undersigned also acknowledges that it understands that the answers to this Questionnaire are furnished for use in connection with Registration Statements filed pursuant to the Registration Rights Agreement and any amendments or supplements thereto filed with the Commission pursuant to the Securities Act.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By signing below, the undersigned hereby acknowledges and is advised of the following Compliance and Disclosure Interpretation (&#8220;<font style="font-weight:bold;">CDI</font>&#8221;) of the staff of the Division of Corporation Finance (with respect to Securities Act Sections) regarding short selling:</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:3.85%;margin-right:3.85%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&#8220;<font style="font-weight:bold;">239.10</font> An issuer filed a Form S-3 registration statement for a secondary offering of common stock which is not yet effective. One of the selling stockholders wanted to do a short sale of common stock &#8220;against the box&#8221; and cover the short sale with registered shares after the effective date. The issuer was advised that the short sale could not be made before the registration statement becomes effective, because the shares underlying the short sale are deemed to be sold at the time such sale is made. There would, therefore, be a violation of Section 5 if the shares were effectively sold prior to the effective date. [Nov. 26, 2008]&#8221;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By returning this Questionnaire, the undersigned will be deemed to be aware of the foregoing CDI, acknowledges that the foregoing CDI applies to the Common Stock to be registered for resale on behalf of the undersigned pursuant to the Registration Statement.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I confirm that, to the best of my knowledge and belief, the foregoing statements (including without limitation the answers to this Questionnaire) are correct.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;IN WITNESS WHEREOF the undersigned, by authority duly given, has caused this Notice and Selling Stockholder Questionnaire to be executed and delivered either in person or by its duly authorized agent.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:&#160;<font style="text-decoration:underline;">____________________________</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name of Holder (print): ____________________________________________</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Signature (individual):&#160;<font style="text-decoration:underline;">_____________________________________________</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Signature (corporate):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:4.32%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:36.24%; border-bottom:solid 1pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;width:59.46%; border-bottom:solid 1pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:36.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:59.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:36.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:59.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PLEASE EMAIL A COPY OF THE COMPLETED AND EXECUTED NOTICE AND SELLING STOCKHOLDER QUESTIONNAIRE TO:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:26.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company:</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:69.24%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Achieve Life Sciences, Inc.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1040 West Georgia Street, Suite 1030</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vancouver, British Columbia, Canada V6E 4H1</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: John Bencich</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Email: jbencich@achievelifesciences.com</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:26.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:69.24%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:26.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With copies to:</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:69.24%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fenwick &amp; West LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1191 Second Avenue, Floor 10</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Seattle, Washington 98101</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Alan Smith, Amanda Rose and Chelsea Anderson</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E-mail: acsmith@fenwick.com, arose@fenwick.com, canderson@fenwick.com</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">FORM OF PLAN OF DISTRIBUTION</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PLAN OF DISTRIBUTION</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are registering the Shares offered hereby to permit the resale of these Shares by the holders thereof from time to time after the date of this prospectus. We will not receive any of the proceeds from the sale by the selling stockholders of the Shares offered hereby. We will bear all fees and expenses incident to our obligation to register these Shares.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The selling stockholders may sell all or a portion of the Shares held by them and offered hereby from time to time directly or through one or more underwriters, broker-dealers or agents. If the Shares are sold through underwriters or broker-dealers, the selling stockholders will be responsible for underwriting discounts or commissions or agent&#8217;s commissions. The Shares may be sold in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions, pursuant to one or more of the following methods:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.14%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.64%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:92.2%;">
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on any national securities exchange or quotation service on which the shares may be listed or quoted at the time of sale;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.14%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.64%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:92.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the over-the-counter market;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.14%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.64%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:92.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in transactions otherwise than on these exchanges or systems or in the over-the-counter market;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.14%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.64%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:92.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">through the writing or settlement of options, whether such options are listed on an options exchange or otherwise;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.14%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.64%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:92.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.14%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.64%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:92.22%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.14%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.64%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:92.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.14%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.64%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:92.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an exchange distribution in accordance with the rules of the applicable exchange;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.14%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.64%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:92.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">privately negotiated transactions;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.14%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.64%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:92.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">short sales made after the date the Registration Statement is declared effective by the Commission;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.14%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.64%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:92.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">broker-dealers may agree with a selling stockholder to sell a specified number of such shares at a stipulated price per share;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.14%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.64%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:92.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a combination of any such methods of sale; and</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.14%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4.64%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:92.2%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any other method permitted pursuant to applicable law.</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU17"></a>The selling stockholders may also sell Shares under Rule&#160;144 promulgated under the Securities Act, if&#160;available, rather than under this prospectus. In addition, the selling stockholders may transfer the Shares by other means not described in this prospectus. If the selling stockholders effect such transactions by selling Shares to or through underwriters,&#160;broker-dealers or agents, such underwriters, broker-dealers or agents may receive commissions in the form of discounts, concessions or commissions from the selling stockholders or commissions from purchasers of the Shares for whom they may act as agent or&#160;to whom they may sell as principal (which discounts, concessions or commissions as to particular underwriters, broker-dealers or agents may be in excess of those customary in the types of transactions involved). In connection with sales of the Shares or otherwise, the selling stockholders may enter into hedging transactions with broker-dealers, which may in turn engage in short sales of the Shares in the course of hedging in positions they assume. The selling stockholders may also sell shares of common stock short and deliver Shares covered by this prospectus to close out short positions and to return borrowed shares in connection with such short sales. The selling stockholders may also loan or pledge Shares to broker-dealers that in turn may sell such Shares.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The selling stockholders may pledge or grant a security interest in some or all of the Shares owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the Shares from time to time pursuant to this prospectus or any amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act amending, if necessary, the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus. The selling stockholders also may transfer and donate the Shares in other circumstances in which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent required by the Securities Act and the rules and regulations thereunder, the selling stockholders and any broker-dealer participating in the distribution of Shares may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act, and any commission paid, or any discounts or concessions allowed to, any such broker-dealer may be deemed to be underwriting commissions or discounts under the Securities Act. At the time a particular offering of the Shares, a prospectus supplement, if required, will be distributed, which will set forth the aggregate amount of Shares being offered and the terms of the offering, including the name or names of any broker-dealers or agents, any discounts, commissions and other terms constituting compensation from the selling stockholders and any discounts, commissions or concessions allowed or re-allowed or paid to broker-dealers.</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the securities laws of some states, Shares may be sold in such states only through registered or licensed brokers or dealers. In addition, in some states Shares offered hereby may not be sold unless such Shares have been registered or qualified for sale in such state or an exemption from registration or qualification is available and is complied with.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There can be no assurance that any selling stockholder will sell any or all of the Shares registered pursuant to the registration statement of which this prospectus forms a part.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The selling stockholders and any other person participating in such distribution will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including, without limitation, to the extent applicable, Regulation&#160;M of the Exchange Act (&#8220;Regulation M&#8221;), which may limit the timing of purchases and sales of any Shares by the selling stockholders and any other participating person. To the extent applicable, Regulation M may also restrict the ability of any person engaged in the distribution of the Shares to engage in market-making activities with respect to the Shares. All of the foregoing may affect the marketability of the Shares and the ability of any person or entity to engage in market-making activities with respect to the Shares.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once sold under the registration statement of which this prospectus forms a part, the Shares offered hereby will be freely tradable in the hands of persons other than our affiliates.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>achv-ex991_6.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
achv-ex991_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.73 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:14pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0aqixktv34q000001.jpg" title="" alt="" style="width:94px;height:104px;"></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:16pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:16pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:14pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"><a name="_j7qbzng8zy6u"></a>Achieve Life Sciences Announces Private Placement of $18.9 Million </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">SEATTLE, Wash. and VANCOUVER, British Columbia, November 15, 2022<font style="font-weight:normal;"> -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that it has entered into definitive agreements for a private placement of its securities for gross proceeds of approximately $18.9 million, prior to deducting placement agent commissions and estimated offering expenses. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk38969616"></a>The private placement will be for up to 4,093,141<font style="color:#FF0000;"> </font>units at a price of $4.625 per unit, with each unit consisting of two shares of common stock and one warrant to purchase one share of common stock. The private placement was priced at $2.3125 per common share, an 8.6% premium to the closing price of the Company&#8217;s common stock the day prior to entering into the subscription agreements, including a one-half warrant per share. The private placement is expected to close on or about November 18, 2022, subject to customary closing conditions. The warrants will have an initial per share exercise price of $4.50. All warrants will be exercisable beginning on the six-month anniversary of the closing of the offering and will have a seven-year term. The Company intends to use the proceeds from the private placement to fund clinical research and development, and for general working capital. It estimates that the net proceeds, plus its existing financial resources, are sufficient to fund operations into late 2023.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk119313506"></a>The private placement includes a new life sciences focused investment fund, participation from Achieve management, as well as new and existing <font style="color:#000000;">investors.  </font>Lake Street Capital Markets, LLC is acting as the exclusive placement agent in connection with this offering. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The securities being issued and sold in the private placement have not been registered under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or any state&#8217;s securities laws, and are being issued and sold in reliance on Section 4(a)(2) of the Securities Act and Regulation D promulgated thereunder.&nbsp;&nbsp;The securities may not be offered or sold in the United States, except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. Achieve has agreed to file a registration statement to register the resale of the shares of common stock included in the units and underlying the warrants within 60 days of the closing of the offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:14pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0aqixktv34q000001.jpg" title="" alt="" style="width:94px;height:104px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0aqixktv34q000003.jpg" title="" alt="" style="width:127px;height:142px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;;font-family:Cambria;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">About Achieve and Cytisinicline&#8239;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Achieve&#8217;s focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline. Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the United States annually.<sup style="font-size:85%;line-height:120%;vertical-align:top">1,2</sup> More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.<sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, there are nearly 11 million adults in the United States who use e-cigarettes, also known as vaping.<sup style="font-size:85%;line-height:120%;vertical-align:top">3</sup> While nicotine e-cigarettes are thought to be less harmful than combustible cigarettes, they remain addictive and can deliver harmful chemicals which can cause lung injury or cardiovascular disease.<sup style="font-size:85%;line-height:120%;vertical-align:top">4</sup> In 2021, e-cigarettes were the most commonly used tobacco product reported by 1.72 million high school students.<sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup> Research shows adolescents who have used e-cigarettes are seven times more likely to become smokers one year later compared to those who have never vaped.<sup style="font-size:85%;line-height:120%;vertical-align:top">6</sup> Currently, there are no FDA-approved treatments indicated specifically as an aid to nicotine e-cigarette cessation.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine addiction for smoking and e-cigarette cessation by interacting with nicotine receptors in the brain, reducing the severity of withdrawal symptoms, and reducing the reward and satisfaction associated with nicotine products. Cytisinicline is an investigational product candidate being developed for treatment of nicotine addiction and has not been approved by the Food and Drug Administration for any indication in the United States. For more information on cytisinicline and Achieve visit <font style="text-decoration:underline;color:#1155CC;">www.achievelifesciences.com</font>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Forward Looking Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This press release contains forward-looking statements within the meaning of the &#8220;safe harbor&#8221; provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the closing of the private placement, registration of the shares of common stock being issued and sold in the private placement, including those shares underlying the warrants, Achieve&#8217;s use of the proceeds from the private placement, expectations regarding Achieve&#8217;s cash forecasts, the timing and nature of cytisinicline clinical development, data results and commercialization activities, the potential market size for cytisinicline, the potential benefits, safety and tolerability of cytisinicline, the ability to discover and develop new uses for cytisinicline, including but not limited to as an e-cigarette </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:14pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0aqixktv34q000001.jpg" title="" alt="" style="width:94px;height:104px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cessation product, and the development and effectiveness of new treatments. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management&#8217;s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that </font><font style="font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cytisinicline</font><font style="font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> may not demonstrate the hypothesized or expected benefits; the risk that Achieve may not be able to obtain additional financing to fund the development of </font><font style="font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cytisinicline</font><font style="font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">; the risk that </font><font style="font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cytisinicline</font><font style="font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> will not receive regulatory approval or be successfully commercialized; the risk that new developments in the smoking cessation landscape require changes in business strategy or clinical development plans; the risk that </font><font style="font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Achieve&#8217;s</font><font style="font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> intellectual property may not be adequately protected; general business and economic conditions; risks related to the impact on our business of the COVID-19 pandemic or similar public health crises and the other factors described in the risk factors set forth in </font><font style="font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Achieve&#8217;s</font><font style="font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> filings with the Securities and Exchange Commission from time to time, including </font><font style="font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Achieve&#8217;s</font><font style="font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Investor Relations Contact</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rich Cockrell</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#1155CC;font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">achv@cg.capital</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(404) 736-3838</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">Media Contact</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Glenn Silver</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#1155CC;font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Glenn.Silver@Finnpartners.com</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(646) 871-8485</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">References</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">1</sup>World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">2</sup>U.S. Department of Health and Human Services. The Health Consequences of Smoking &#8211; 50 Years of Progress. A Report of the Surgeon General, 2014.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">3</sup>Cornelius ME, Wang TW, Jamal A, Loretan CG, Neff LJ. Tobacco Product Use Among Adults &#8212; United States, 2019. MMWR Morb Mortal Wkly Rep 2020;69:1736&#8211;1742. DOI: 10.15585/mmwr.mm6946a4</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">4</sup>Ogunwale, Mumiye A et al. (2017) Aldehyde Detection in Electronic Cigarette Aerosols. ACS omega 2(3): 1207-1214. DOI: 10.1021/acsomega.6b00489].</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">5</sup>Gentzke AS, Wang TW, Cornelius M, et al. Tobacco Product Use and Associated Factors Among Middle and High School Students &#8211; National Youth Tobacco Survey, United States, 2021. MMWR Surveill Summ 2022;71(no. SS-5):1-29. DOI: 10.15585/mmwr.ss7105a1.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:14pt;font-family:Cambria;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g0aqixktv34q000001.jpg" title="" alt="" style="width:94px;height:104px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">6</sup></font><font style="font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Elizabeth C. Hair, Alexis A. Barton, Siobhan N. Perks, Jennifer </font><font style="font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kreslake</font><font style="font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Haijun</font><font style="font-family:Calibri;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Xiao, Lindsay Pitzer, Adam M. Leventhal, Donna M. Vallone, Association between e-cigarette use and future combustible cigarette use: Evidence from a prospective cohort of youth and young adults, 2017&#8211;2019, Addictive Behaviors, Volume 112, 2021, 106593, ISSN 0306-4603. DOI: 10.1016/j.addbeh.2020.106593.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:14pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g0aqixktv34q000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0aqixktv34q000001.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0""17AI9@  34T *@    @ !0$2  ,
M   !  $   $:  4    !    2@$;  4    !    4@$H  ,    !  (  (=I
M  0    !    6@        "6     0   )8    !  *@ @ $     0   -N@
M P $     0   /0       #_X@?H24-#7U!23T9)3$4  0$   ?887!P; (@
M  !M;G1R4D="(%A96B 'V0 " !D "P :  MA8W-P05!03     !A<'!L
M                    ]M8  0    #3+6%P<&P
M                                          MD97-C   !"    &]D
M<V-M   !>   !9QC<')T   '%    #AW='!T   '3    !1R6%E:   '8
M !1G6%E:   '=    !1B6%E:   'B    !1R5%)#   'G     YC:&%D   '
MK    "QB5%)#   'G     YG5%)#   'G     YD97-C         !1'96YE
M<FEC(%)'0B!0<F]F:6QE               41V5N97)I8R!21T(@4')O9FEL
M90
M        ;6QU8P         ?    #'-K4TL    H   !A&1A1$L    N   !
MK&-A15,    D   !VG9I5DX    D   !_G!T0E(    F   "(G5K54$    J
M   "2&9R1E4    H   "<FAU2%4    H   "FGIH5%<    6   "PFYB3D\
M   F   "V&-S0UH    B   "_FAE24P    >   #(&ET250    H   #/G)O
M4D\    D   #9F1E1$4    L   #BFMO2U(    6   #MG-V4T4    F   "
MV'IH0TX    6   #S&IA2E     :   #XF5L1U(    B   #_'!T4$\    F
M   $'FYL3DP    H   $1&5S15,    F   $'G1H5$@    D   $;'1R5%(
M   B   $D&9I1DD    H   $LFAR2%(    H   $VG!L4$P    L   % G)U
M4E4    B   %+F%R14<    F   %4&5N55,    F   %=@!6 6$ 90!O &(
M90!C &X _0 @ %( 1P!" "  < !R &\ 9@!I &P 1P!E &X 90!R &4 ;  @
M %( 1P!" "T 8@!E ', :P!R &D =@!E &P <P!E %  90!R &8 :0!L "
M4@!' $( ( !G &4 ;@#H '( :0!C $,>I0!U "  : #L &X :  @ %( 1P!"
M "  0P!H '4 ;@!G %  90!R &8 :0!L "  4@!' $( ( !' &4 ;@#I '(
M:0!C &\$%P0P!#,$, 0[!$P$/00X!#D ( 0_!$ $/@1$!# $.00[ "  4@!'
M $( 4 !R &\ 9@!I &P ( !G .D ;@#I '( :0!Q '4 90 @ %( 5@!" ,$
M; !T &$ ; #A &X ;P!S "  4@!' $( ( !P '( ;P!F &D ;) :=2@ ( !2
M $< 0@ @@G)?:6//C_  1P!E &X 90!R &D <P!K "  4@!' $( +0!P '(
M;P!F &D ; !/ &( 90!C &X _0 @ %( 1P!" "  < !R &\ 9@!I &P%Y 7H
M!=4%Y 79!=P ( !2 $< 0@ @!=L%W 7<!=D 4 !R &\ 9@!I &P ;P @ %(
M1P!" "  9P!E &X 90!R &D 8P!O %  <@!O &8 :0!L "  4@!' $( ( !G
M &4 ;@!E '( :0!C $$ ; !L &< 90!M &4 :0!N &4 <P @ %( 1P!" "T
M4 !R &\ 9@!I &S'?+P8 "  4@!' $( (-4$N%S3#,=\9FZ0&@ @ %( 1P!"
M "!CSX_P98=.]DX @BP ( !2 $< 0@ @,-<P[3#5,*$PI##K Y,#M0.] [D#
MN@/, " #P /! [\#Q@.O [L ( !2 $< 0@!0 &4 <@!F &D ;  @ %( 1P!"
M "  9P!E &X Z0!R &D 8P!O $$ ; !G &4 ;0!E &4 ;@ @ %( 1P!" "T
M< !R &\ 9@!I &4 ; Y"#AL.(PY$#A\.)0Y, "  4@!' $( ( X7#C$.2 XG
M#D0.&P!' &4 ;@!E &P ( !2 $< 0@ @ %  <@!O &8 :0!L &D 60!L &4
M:0!N &4 ;@ @ %( 1P!" "T < !R &\ 9@!I &D ; !I $< 90!N &4 <@!I
M 0T :P!I "  4@!' $( ( !P '( ;P!F &D ; !5 &X :0!W &4 <@!S &$
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M   ][@   ]!865H@        6G4  *QS   7-%A96B         H&@  %9\
M +@V8W5R=@         ! <T  '-F,S(       $,0@  !=[___,F   'D@
M_9'___NB___]HP   ]P  ,!L_]L 0P " @(" @(# @(#! ,# P0%! 0$! 4'
M!04%!04'" <'!P<'!P@(" @(" @("@H*"@H*"PL+"PL-#0T-#0T-#0T-_]L
M0P$" @(# P,& P,&#0D'"0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0T-_\  $0@ ] #; P$B  (1 0,1 ?_$ !\
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M;D9GMPJ_>9@H:/Y6.]0HP'8U^0)-?T,5^3?[6?P='@+Q</&.APA-"\1S.Y5
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MDMR5AE)7)!B=F9W;'V]X\\%:-\1/"6H^#]>5C::C%LWH</%(I#1RH?[T;@,
M>#C# J2#_+U\#O$OCOPI\7/"NL_#)//\3+J4$&GV[<QW+W)\EH).5_=S*Y1S
MN7"L2&4@$?U9C.!GKWK\=XQR>E0Q+LER5$W;\UZ/_@=#[WA[-*Z4:U.3C4IM
M-26]UJFO-'X"^,O"FL^!/%&I>$?$"*E_IDYAEV$E'& R2(2 2DB%74D E6&0
M#Q7,9K]5/VPO@]_PF'A7_A8FAQ9UCP[ WVM0V//TQ-SOP1R\!)D'(^0R#YFV
M"ORF)]#7\PY[E,LNQ3H_9>L7W7^:V9_H3P#Q=2XBRF&,6E2/NSCVDNOH]U]W
M1DNZO6O@O\4;[X4>.[+Q- &DLG_T;48%&?-M)"-X R/G3 =.?O*,\9!\@R:7
M..]>5A\34H58UJ3M):H^HS++:&/PM3!8F-X3337K^O5']#&F:G8:SIMKJ^ES
M+<6=["EQ!,GW9(I%#*PSSR#WYJ]7YT_L8?&7:S?"+Q!.,'S+C19'SUY>6VST
M]9$Z<[ADDJ*_1:OWK*,SIX_"QQ%/YKL^J/X$XOX9KY#FE3+J^J6L7_-%[/\
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MO:?_ !VJEQ\<O@U:H7D\;Z 0/^>>HP2G\D=C7.\;AUO47WH]&.2YBW94)_\
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MNGY,<3BOU+_8<^-W]J:>_P 'O$4_^EV*//HSN1F2W&6E@SG):/)=>"=N[H%
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M_P!<JG_/I??_ , 7]C1_F/XV3X/\7CKHFH#_ +=9?_B:;_PB/BP?\P6__P#
M:7_XFO[***?^N53_ )]+[_\ @!_8T?YOP/XUO^$3\5CKHU__ . TG_Q-)_PB
MGBK_ * ]_P#^ TG_ ,37]E5%'^N53_GTOO\ ^ ']C1_F_ _C5_X13Q5_T![_
M /\  :3_ .)H_P"$4\5?] >__P# :3_XFO[*J*/]<JG_ #Z7W_\  #^QH_S?
M@?QJ_P#"*>*O^@/?_P#@-)_\31_PBGBK_H#W_P#X#2?_ !-?V544?ZY5/^?2
M^_\ X ?V-'^;\#^-7_A%/%7_ $![_P#\!I/_ (FC_A%/%7_0'O\ _P !I/\
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J/<URFG_\A8?[]>FCI6G#E.-IRMKM\NQCXAUJB=*DI/EU=KZ7[V[^9__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g0aqixktv34q000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g0aqixktv34q000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ". '\# 2(  A$! Q$!_\0
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M.-C@J3YY7-KPMX?N/$VO6^GPY",=TT@'W$'4_P"'O7TW8V4&G6,%G:QB."%
MB*.P%<E\-_"8\-Z"L]P@&H7@#S$CE!_"GX=_<UVM>?B:O/*RV1U4:?*KO<*J
M:I:O>Z7=6L94/+$R*6Z D5;HKF:NK&\6XNZ/,O\ A76J_P#/S:?]]-_A2?\
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MKMMK;^K&C8X-C"5GDG!7(DD&&;W(P/Y5D:]<SPW]NDMQ<6FG-&Q>X@7)#Y&
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0KV30H\MY*6B[_P!+_(__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>achv-20221114.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-11-16T00:02:46.5457558+00:00 -->
<!-- Version            : 5.0.1.753 -->
<!-- Package ID         : 3ed8278c53cd47ce87c98e26b4d97270 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:achv="http://achievelifesciences.com/20221114" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2022" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://achievelifesciences.com/20221114" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" namespace="http://xbrl.sec.gov/country/2022" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" namespace="http://xbrl.sec.gov/currency/2022" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" namespace="http://xbrl.sec.gov/exch/2022" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" namespace="http://xbrl.sec.gov/sic/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" namespace="http://fasb.org/srt/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd" namespace="http://fasb.org/srt-roles/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" namespace="http://fasb.org/srt-types/2022" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" namespace="http://xbrl.sec.gov/stpr/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd" namespace="http://fasb.org/us-roles/2022" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" namespace="http://fasb.org/us-types/2022" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://achievelifesciences.com/20221114/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="achv-20221114_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="achv-20221114_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://achievelifesciences.com/20221114/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>achv-20221114_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-11-16T00:02:46.5457558+00:00 -->
<!-- Version            : 5.0.1.753 -->
<!-- Package ID         : 3ed8278c53cd47ce87c98e26b4d97270 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Country</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>achv-20221114_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-11-16T00:02:46.5457558+00:00 -->
<!-- Version            : 5.0.1.753 -->
<!-- Package ID         : 3ed8278c53cd47ce87c98e26b4d97270 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://achievelifesciences.com/20221114/role/TemplateLink" xlink:href="achv-20221114.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://achievelifesciences.com/20221114/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="achv-20221114.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://achievelifesciences.com/20221114/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140291183531200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 14, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 14,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ACHIEVE LIFE SCIENCES, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000949858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">033-80623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-4343413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1040 West Georgia<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Vancouver<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">BC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">V6E 4H1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">210-2217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ACHV<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>achv-8k_20221114_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="achv-20221114.xsd" xlink:type="simple"/>
    <context id="C_0000949858_20221114_20221114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000949858</identifier>
        </entity>
        <period>
            <startDate>2022-11-14</startDate>
            <endDate>2022-11-14</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="C_0000949858_20221114_20221114" id="F_000001">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="C_0000949858_20221114_20221114" id="F_000004">0000949858</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="C_0000949858_20221114_20221114" id="F_000000">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="C_0000949858_20221114_20221114" id="F_000002">2022-11-14</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="C_0000949858_20221114_20221114" id="F_000003">ACHIEVE LIFE SCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0000949858_20221114_20221114" id="F_000007">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="C_0000949858_20221114_20221114" id="F_000006">033-80623</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="C_0000949858_20221114_20221114" id="F_000008">95-4343413</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0000949858_20221114_20221114" id="F_000009">1040 West Georgia</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="C_0000949858_20221114_20221114" id="F_000010">Suite 1030</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="C_0000949858_20221114_20221114" id="F_000011">Vancouver</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0000949858_20221114_20221114" id="F_000012">BC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry contextRef="C_0000949858_20221114_20221114" id="F_000013">CA</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="C_0000949858_20221114_20221114" id="F_000014">V6E 4H1</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0000949858_20221114_20221114" id="F_000015">604</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0000949858_20221114_20221114" id="F_000016">210-2217</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="C_0000949858_20221114_20221114" id="F_000017">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="C_0000949858_20221114_20221114" id="F_000018">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="C_0000949858_20221114_20221114" id="F_000019">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="C_0000949858_20221114_20221114" id="F_000020">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="C_0000949858_20221114_20221114" id="F_000021">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0000949858_20221114_20221114" id="F_000022">ACHV</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0000949858_20221114_20221114" id="F_000023">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="C_0000949858_20221114_20221114" id="F_000005">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MJMW[@]V.D6G^S+Z0QL@XWUQS!@5G3X#C2RG-8<>^!BC>X@S^ U!+ P04
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MJ'7N0;#W\!J-'<V/'[?\ 5!+ P04    " "S@')5)!Z;HJT   #X 0  &@
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4 -5"I0P5,
M75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K!LIDR^SO
M *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1UW6E\./VR
M./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/
M3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ LX!R5660>9(9 0  SP,
M !,   !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +
M77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5
M!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP
M39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM
M2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>
M,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]
M#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4
M" "S@')5!T%-8H$   "Q    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( +. <E6Z5:/6[P   "L"   1
M  "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( +. <E697)PC
M$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ LX!R5?2&11")!   T1$  !@              ("!#@@
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( +. <E6?H!OP
ML0(  .(,   -              "  <T,  !X;"]S='EL97,N>&UL4$L! A0#
M%     @ LX!R59>*NQS     $P(   L              ( !J0\  %]R96QS
M+RYR96QS4$L! A0#%     @ LX!R51PX9>H_ 0  / (   \
M ( !DA   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( +. <E4D'INBK0
M /@!   :              "  ?X1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( +. <E5ED'F2&0$  ,\#   3              "
M >,2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  "T4
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="achv-8k_20221114.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://achievelifesciences.com/20221114/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="achv-8k_20221114.htm">achv-8k_20221114.htm</File>
    <File>achv-20221114.xsd</File>
    <File>achv-20221114_lab.xml</File>
    <File>achv-20221114_pre.xml</File>
    <File>achv-ex101_54.htm</File>
    <File>achv-ex102_53.htm</File>
    <File>achv-ex41_55.htm</File>
    <File>achv-ex991_6.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "achv-8k_20221114.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "achv-8k_20221114.htm"
     ]
    },
    "labelLink": {
     "local": [
      "achv-20221114_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "achv-20221114_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "achv-20221114.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "achv",
   "nsuri": "http://achievelifesciences.com/20221114",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "achv-8k_20221114.htm",
      "contextRef": "C_0000949858_20221114_20221114",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://achievelifesciences.com/20221114/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "achv-8k_20221114.htm",
      "contextRef": "C_0000949858_20221114_20221114",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://achievelifesciences.com/20221114/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://achievelifesciences.com/20221114/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "verboseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://achievelifesciences.com/20221114/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://achievelifesciences.com/20221114/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://achievelifesciences.com/20221114/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://achievelifesciences.com/20221114/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://achievelifesciences.com/20221114/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://achievelifesciences.com/20221114/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://achievelifesciences.com/20221114/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://achievelifesciences.com/20221114/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://achievelifesciences.com/20221114/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://achievelifesciences.com/20221114/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://achievelifesciences.com/20221114/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://achievelifesciences.com/20221114/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://achievelifesciences.com/20221114/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://achievelifesciences.com/20221114/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://achievelifesciences.com/20221114/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://achievelifesciences.com/20221114/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://achievelifesciences.com/20221114/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://achievelifesciences.com/20221114/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://achievelifesciences.com/20221114/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://achievelifesciences.com/20221114/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://achievelifesciences.com/20221114/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://achievelifesciences.com/20221114/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001564590-22-038025-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-22-038025-xbrl.zip
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M38.&/"V'F$4H%X<J\L[+W,[YUSWENV?NM7=8>8N5:H7.E_)+X_8G4$L#!!0
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MMO *!T$=8_!Z"MD$D<D?C+X$3STZG;FDXGD[!Z))/I20.QN8"1N(Z$#,9\H
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M6X'G >$A,M$T#&<-VUXNEY8_IEP)-@\AN[*P"&QDFG'HMB2>OH!NO9"@Z--
M):=4,EW7=*^&CM-P2HW*E56M5&O5ZO4O^H2S%^"O3;/0WJ>!JI9CN5:M6MXS
M['GXV9L0U+G=,RP3_[I4N\;5,O8K-4RN:[A^34I7HXI?KY5J^XG:8K:6=#(-
MT3O\/H(([>6<,$;6Z)YRCV/J,32(6_HKZG!LH19CJ*_=%.H31>2"^-8V*@/>
M&BPF#^X15]'?IK''WFHDF27DQ"XY3MF.K8VM^>K(?EF.K-UZO6Y'5W>FBIXR
MA+"N_>FA.\!3$G@FW"JH JP3*-I0T<FNP-$].@,72K70_\S8S-2G3+=DEEUK
MI7P#V$!HPX<4C/3)&.G?/_N=74X/3RE9$$;'!*H5RI=L:DG?"-=U*[9VL(<D
MF#&HI.ZFX5'$J23CI@'^"S,VUDE_/F4;KF=0_(K"%:# S@)7Z*T$%\%Z S!^
M1.+?%O?O>$C#=8>/A0PBGE\#WH= GR\)E-ZJF82:Y&%DK7DX<""KD'"?^'$8
MW8!<VQT!BZ$Q@0]XT'D5)([*2A%L3<3"]@F-,NJ#B*2((/CS>4#P7$+\NQ6>
M>GQ"'KV '/+!=%D+&9]DWHBPII'N:V<);R@]+;^#=3 2[%Q<+YPR!12WV2V-
MAC1D%W.5^&4*JR=)6P2!KB]=-AVEYD0.=5G*I_&8R'-AOAXG3]A?#S@_J-!A
M44Q#J*L'$$,)?=C9M_Z$9Z;0_H;" @G2/,PYW71"ZEQT*<Z9 M0](^M-8<3T
M. ]&Y]_<8[],8;7A>6S!P*HM_+.?XT.?3.%LA+[E^]#9J)Z  0;[A\XN ?>E
M"/E!;8LY#^7Z32!WOOG!&T"W39YD3XH%W8S8+H=Y%"-'-N'P20[%DK^-T#WW
M_$!N?V H1$IO@GD8X)L =;\6J)L+T*&WZOC0<]'Q5GPOD\A7@N0 &*9K0LZ$
MC/)$#\;V(;Y<J5X)E0/X>\HN[(.._7* =1<0.8$!PN]2+,,I],4SCU\HJ"DA
M<@#;AD*3'NO 2&OU![D0YI%S#@#[9$(59.'A);.9T[Z9PHMG=3T8!0J8V/EZ
M->=<?"G.F0)L00)?)[EGWN1<8"^<<F%L"!@N)6KCD^V(42R(;(UT@>#P["'C
MH=,AH/V5A9;$!R$]B>-P<'BPK'"\<+2UL&>>A'@FGE*V6Y$82Q&<Q++-)DX1
M)R3,I)J&ZSBN8SF.@690=WH*VS2@RYXK "-F&K:>ST S8,HEB=_=M#L59H01
M9D&*1);_93I>U'7"1[F8?*0(4,)+-6M> ,Q(? ?,G.XZ$F)JQ2R8E!X_X:5>
M9%Y2!FP[=MR"RN[Q@#NAI*#*>]9L*6$I<QW^GEA*G0HG_!1:CD^N:R3<%%J2
M3RY.[;@I%5J03ZPO)LP46I?3UH@3>@HMR"]7^A-:_M?AH[<T"3D%%>+#]VL[
M.LH%U=[C-Z ))045W907U@DO!57;4]L,$E(*JK5?VAZ2D%-0K7U]L\^.HDI!
M]?=XVU9"24'U]\7NNH2/HNKNR5V0"2W?0'EO["-68/+ZK#=/;Z[H+[VA^,._
M4$L#!!0    ( +. <E4 5+C@+A@  +2Y   4    86-H=BTX:U\R,#(R,3$Q
M-"YH=&WM7?]SXKB2__FNZOX'77;W55('QC;?269>90G9Y>U,)A<RLUOWRY2P
M!>B-L7F6G83WUU^W9!L;# $2$B9#MFH'L+ZT6MV?;K5:\MG?'\8.(7?,%]QS
MWQT9FGY$F&MY-G>'[X["8%!L'/W]_7_]Y]E_%XODXK)[1<ZM@-^Q"RXLQQ.A
MSXY['T](UW6XR\A?O]Y\(!>>%8Z9&Y B&07!I%4JW=_?:_: N\)SP@#Z$9KE
MC4ND6(P;;ON,X@-R00-&Y%^+F+II%@VC:#1NC6JKVFP9=4UO-AIZ0_\?76_I
M>JJ!+VH )/77(E5-UPRM7BVG"EY3ZQL=,M*]2!4L,[MAUAM6M6S9E;K%&G6K
MV6!FK5^QFW6SGNZH[4VF/A^. G)LG4@28;RNRQR'3<DE=ZEK<>J07CS2 K#&
MTLBYXY ;K";(#1/,OV.V%K4Z"F &8!9<T7KH^PY_=Y3B&OZB>?ZP9.IZN00<
M#* #=I0J;\\JI O72NIA7)1:H[ND('SA[(XY?,"$Q6&ZF9H1'(YA&)6X4BB*
MP73"1%)Q0$5?]A _D552Q8>43G)+XX-,81%,_"SE@EG:T+LKX9-,43OPY^C(
ML 8>E_ QUM&+NE$TC:03/U@V@N11EBH_R"V:+<2M)91S*U/0I=P2^47EHTQA
M]F"-\LOBDRQ#&,\O"0\R!:W0]V%ZI_FEXZ?9*E[H!OZR&NIAEFXW')MY,FCJ
M0'G 7,'[#BMB,>9++1=%$V$FDF$ CF^9B;TORP:,9K-9DD\3^0K\I<K1+,'3
MN.!"DUDUPL=]*A(UXL*KF$9]E>*I$@G-@N=1#$6-TE\?/_2L$1O3XKRV\H=E
M/1BHV@B@B)^)\ "LA.-'1!X*%25CN974>[Q2M@)_"/(KS&@J!3YUQ<#SQW("
MD>1J43>+9BW52!&D)--0+#6/M=,HEF.-72X(")-'$B\9M?'?,0NH-#!%]J^0
M [BU/1>D+2C>PAB/B*6^O3L*0 A+LC8I8;V !PZ##XB(Q<:WKS'H:5 &'I?B
MYV>EN"?$_:O? /I=L),!\\D=6A93J\>&I>_9T_=G-K\C(I@Z[-V1S<7$H5.<
M0X9$_\<9?VAA<\S';^HKMVWFRJ_R.Y2]4A-#N/WNZ/*KCG_ &)>.L4G&6^=@
M5FTTK9<.'49#? ANV  &+XLW*\U&M9$,*?EP]'Y '<'.2IE^'NN[DNZ[XP)C
MIFWHW*=.U[79PQ]LNAD-LZ=YA,C?4DQ!NGPV8+ZT3Q&MJ+HM(?4+NB02'EHH
MU.^.!!]/'%0V^=O(1XKD'"<3_"#L^#'U+=_#F5H;)#; J77AY_U9*3N>&1_F
M!JYX(;S0G[%".@NMB/]RVA[COZP75V1R/J/?XA^YC3\/.,BX)(KEZG.[^T=V
M,N<KQSV5<KJ*>IK O'OV7/> EWZ +N#[Q/>KQ(W,GF7K@$8LJ1$_R1*3[CC^
M+6)BFOTI7BO!C)7WK 1ZCO].8F4?4W_(W6+?"P)OW-(GP6GT2^!-Y%=L&ZP!
MLJ>E_W(Z@-Z* SKFSK1UR\=,D"MV3VZ\,775,\'_S5H5J'CT_F\_&37]]*PT
M>8$>C14]R@:IPX=NRX)&F7^*D%X<,?1I9<V^YP.#) 7@_'*;Z.!Y3P+RDX02
M_71";5Q3)"1N-8:$,X^.Z%Y1YJ*I<:+*.)3X%]EZ8HTD4*M2=]3G%+HD4<'U
M.9*B'QGR*(/PQS17C%RN?*]LR)_8RI(1173V/<=.2V1CG3%N.Z#/5]W;S@7I
MW9[?=GKDB0-;-E6O,;!>I_WYIGO;A5&=7UV0SE_MW\^O?NN0]J>/'[N]7O?3
MU8N-]G'0,6).;#O:/ZD8@0H%GEL@%UI;@T5YM=+<:H21BD:_)%JZ@&%1 >.Y
M@#?AP;ZI:VV/I/KRT\U'LMQ9U=/.:AR"2BT%UO11&\4_YIW3@RB]J"B] &0
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M"&2D. $9B@1Z@7:#47!E!+ JX-9-%5PYG,],JQ@F#Z\W$X4+Y\RJ,>V.3!^
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M&S^N],KX:FIARU9CGB,5"\ZT-JU&&"&U&90 /ALR6RL#FA7J&M> 6.F;5JO
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MPC&IS7+MRM%NOCSG&$:]1C%.:[E*.6&;.6%!G21QMMIDK25$6EZ*A-@*9LS
MA26\0VW2D_&ZPK75EG^9QDR.^Y=',GM$FX9(_KGM#[EEDO.14U-=3-F;B79Z
MNQ$/XVS<NN^B"N;!AT13,G7[04A]W6R+)BQY+>?#Z5LSKN"A@'>YC^@SQS<2
M_VP)^SDDDGK'1!B84I^5#T9E[*EE=ZH+-/52&7&BN28F49>U)3(32=$Q]LY$
MM^0;D\^?>2#JHI"C!>*&%T.\(?;?2(+E.>VU: ALF%O%(%^QXAJZ\!SD(# 6
MUAXXN>U<,FVM7M.J1"Q;6,=\UV*^?]TE\ZW>$G%U^U/M?V9%NG_:1_V0P;H\
MX-3P-.AA?!_W4:]*(@-,"XR,<GP<'"#;UKGN=NVO9J&U&]Q6":!F"/1DF"$K
MX:&]K*5[54OHG!Q1\G,[N S#M&#M( '.(UME?8C>R8HD]CUK:1Y";>5CDTMO
M?5UELG:E;RDV5'PZ Q+ S&YB]OAIVU.@;8M-X7Q(7QIRL0+HV$>8!8Z( 9C(
M9%!A%M<XPAMM27GT?G"-#KTH%J; N%$QA0V96/1R[#0L)7H$_&(S+]QB""XJ
ML(D*1L)P/E6*#"VC>BZ?.V"0H8+K)XBPE"0C;%>*]5OT"Q6#&$"$,O]<!$H$
MFTO""Y=H)TX0>>W#V38%B&UIAA;TD3&R").(3@.:BP2D-LWS^>MGSRXN+OHY
MNEK[D^3\63)6/IF()N>U9U8]2=6L>?XTZ(UK0#1JEY6QZ8@.7Z<E"TFNP08(
M]Y?8-F-KVRMHQLJ*>75>1#XO__$&&W(^G?(\=O?@6 D!WE>1' QL^Y.?=G]\
M!@.TSFB'_E>CR9;%?>4,9 )7-' ,$AC#,5D^9AF.)+I'DG%^,66 @UIE8N:Y
MXX#ACT:WRWJ(LW4:W%H:G%*W&M(F/^=K;VMWNZKR@V&QM^V"R/DLW",!N#2_
MMK0BA$>?4X5QWO#?H)UP3GF^0-A18*N]G?=,U3FI-"#48HUYE52*@5*HM)R<
M5V&]VXO*1)>7XDI['TS:G(C?#_%I8ZW;@^I5=Q'[^^BF+$K!O' +RTJD/2]6
M,ZZD!_%L[P17@C=@^5S97SK:Z"G#^OI@=6E,FAQI:6[I&.#&EC*>/2PWG'/.
MCE%J3<NC-+&(OL;UBR=E$E^:?Y3$%DGKJH-Q@EI$?C3BK:(^:%^34HI?P@2!
MNO5,=8X4J\6.YG/4DR6-_)(,<3$FJD=:[P7AY(C+;-PH='VJ60-9]++>]%P>
M4(L34'-WJJ6L'P,<DU3YL3TN*A-BK@DNN #+&K](/;D6E$?NSS@JR8.(MRQ0
M<IM/9&6(WAD"V$O$Q0C<^"<P3E:)Z].RL&=JIKD(TM8ML$)O2B0% [<%)G2"
M"<>40U4U*7KU \1- <F1U!VV< 18 ,1YSKY-%V 43C]"]TQ[TF$8R.6!K^)5
M65;'T SNU,Z*#K'>E[A1M9H5&;IFY Z4&TFEIV5R3J,B*:RZ.YQ$!RSARM#"
MK*0[! GB3#;R'MKLNXH%UZBX77*1*A#?S28Q+.[9UC$)'2E?C$Q75 !)ZV,\
M'*JI#30FX1/%&\L5,5[:_Y[ZN-,$LHCFY&<NI@YD!E1$IS,WRD'L, /**TU6
M/1N!U$NLR=)I'&MI'*-1IW'<7XT#Q%/(N:?D:D"?/!D!WCB<%*GN?:7]L+?2
M@+BOA@S%!DSAF,>WZBOG\/QA;L8,&"&S=A:8!BM-?^4L7CS,[>#.7"NNC>?&
MH3(!U1Z[^:_C),E!'= 84XN2BTZXK"5<?/\V^V>V20 34@I,[P:L]"-'-F)^
M<2&@0 9A_TMUH^Y-XR%_"Z^Z)E1Y0YQ)M0^&3.=)%HI5UR/;#'$'%E)^X0!B
M24>4."!0, ESFL2(BNO;H#9AG9#GSKK99V%)77!5[41-NQ3R[H!2-3D.OU#A
M4@"C81)5;EN*94F$:4A8*XW-N](DQA8RYHM44"EF./Y2)OQ67E*%,R1].@X*
M4"7-H9?A&%8\&B/,5$@9\9D!92"5F[IAN[M%'0O:QGS>,F9846FK':WQRW:@
M$B4-+18@-$PN"IH#KE@8Q7E?M$S$Z:7 2=OF:2?.X:"F5M^)4[(#"#3.?+K(
MB+\R=?BV^L <E4T9<)L.% (59NYHQV378K)!<(M,]JB\J6T-H"Y'%\.^+5G(
MV/2:L;?*3)9J \YQF&8<)55^WJBFZMGN"]:D9<N15?(:8,L*Q+.>3?C$1(Z:
MY2^(5(N22BW8FX/PA(O8^K)- "EE%[HK(J[!2Q;;Q!?1%\.Y@.C^2+5X:\K^
MC4MPVMT*;TP\P;ZQ;#;5:GQ,__+5XU1+Y>TQ5[-BB<'\M5UC;$L&9[0?GM2\
MR!O3L1N\:EE;/MJ!Y*G$%BXW*;#/Y!4#FXERC:B3!5]SC,.VGO(UK&C\=J5;
MC0-(5"D(:TR.T7*69!\P.!FG=I+3E>25T\[&5.(SV:FH1$ER^U55'5BK6@]3
M&>647'HT(*?YFHNXO(_(=M\[3'(<T6Y")16X5P>,4U78GV=MVV,$3A/\K4I
MRIL5$;K85"P]8:P-CG*1D.7T%%M"8TB,<!$S+#?%5Z#[<@S6!>9<X=.82DT_
M5+]B$M667(VVV=L_.AEKY&)OOE%RHX42F@RH)0DLXP8OPE67K2*T*10WLXC>
MY4$$@ON3]CF*\&2H=5^;G)'Y$"GP_IC36[8DI@:\,$Z;T)&!'Q6]&.FNY-95
M9DT#+TTC[WN.9#0(D39G@T&8#3!\1<T!RO1(N?G7$Q3%((,9P6)$<(S_>K+S
MQ$.T2%$7[.]S# 7([\*6^ E4&0C>\K7YX8W'N0U[E-KP8Y["_P/S4.5/S_(
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M5!_;[@+Q:P7BM;Y+O& ''H72]F,.:85S21.GCD]TWB<V==S[Z)2<#+](^<3
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MVV*"9*.4SG/=.HOM>T<:V.?]4M+H&/\ZC'\RN>N\ZIB=Y2WTD;J5-.CVIJ^
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MO+&$J<8 ,8.BS;QWK>F-2QQWU<,7%NG2DGFFG?VY/&]I4D+%V\;I-;GM_60
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M.#>,IA_W/G<6Y]6QBKOVIO<$+[$5EM(['IR<'0Y/3G\Y..YY^T<GQT<G P3
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M2(FS,%9IJ'0@CM-P$ @IWJE$7LI<">#<F6%>7(FZ^4+>9M.93.>-901"P36
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M:F]@UK6J'? .689,:ZL0]#N])JNZJ4X_&L5)#'=F0]%$\0!*>//VP'N?->.
M_IV!C,C-)W!WQR ^HCB'AQ/X#M4!]Q=<;46>)3 F6 OFCP2E%>BP^"0(+V1$
M^&H*5H%]@B80L%SBM_0,N0:::2<[+AIBTUAKD#=U]FL16ZVZ$W$IW5._#<X&
MX@PLM!S$E]%MCKZ"@I2.26,UK^D5G,UD(I 89T46?OE6-C+21^-8UCHQ]DX
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M#AMZ<VS:JEP>T6]7)*1=9'%4%S09(2Q1;(Q3)N#/H?-TVC1+F=A:!C[])$F
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M\H%(J0C!*&2QP^)PF&5?,-LFG_ME)"Y!%27.T@3D6JZ1%(4I^%.JD2+<5:'
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M8ERKZ>I+.BY1'U_F%$)'"JZ3A=N W$$@\$LJ7F.OD'%]S"P$ 6%(^+L2:]%
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M\-OYAT^GQ__OZ)TX._[EY/#\T^D_>F;>* G<WVK]K?9 ;[7:J7_L8?7OG[[
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M#GX<%YK-?Q(/5^G@':\"T:9(Q8M9KB3PD-7#4 P=@\Q!E0/=$ E:B=7@*'-
MI8.G:\^MIM%;%:]!Z@"G@O]$VE7Z$<O7)2I2W4N"7TO4=(S#!-9F38*:2LL&
M+3X-@CN*BTJY7::-6?';VZYKO*J%(\Y'C@R3B/A&>3IUG.* TAXT_R RD\Y
M?X5U,3-=RASF4!CFTV4XJ0V 'IH0#J T)H U#!X'YZR1=MY'\/H(WHUK](X^
M?CP^^46<G7]Z^^^F=P2QT]]^.SH[/_YT<G)X?+JABN!&MY/9'>SNWSX2P\*^
M+3LA=YE'-#CX#BWU%E;[;4E#-^79O<$=4_/'%X,7FTM.1$\=K)QO=:UU[ST?
M'+S\2VWE.^:S7N*ML0S84/GV8'(@M^3V78NX%HK>Q)!9(R*_+Y-$?"1?-XI
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MF2,CP-;BK;UD#[ZIP<ZJO8-NP]+^Z>DPB^9H<#^=%-,$_O'_ 5!+ P04
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M.3QJW'S_X SONO/3[FX<[</O[X[@LL-H"Z_[CW_[\>G3[9?^Y?3ASLM>C*\
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M$<^W#>8U;,V@#SM&5'&N+RNND-.,)\+-]-T.<XWOS0R=].Q50-;<XW4#DMV
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M/]K246 ."R.H@5KPD*W&3>Q3>0$"F;NMY)O=0]?X;CAFPO1S))>]XL0;+PP
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M0;^SRV:@F'B[ 8?8*1,0V-!WX#8$388$ 5;;A6(&]$F0)*$D@* ;J^)+$@5
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M'JDW7<Z0F'@RC3)4DWZE;SS:(/*FRF'GVY=(563+4I1/F/PL&88E?F)LT[R
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M2P$"% ,4    " "S@')5-NQFLK<$   >%@  $0              @ $
M86-H=BTR,#(R,3$Q-"YX<V102P$"% ,4    " "S@')5IV40E5 '  "\3@
M%0              @ 'F!   86-H=BTR,#(R,3$Q-%]L86(N>&UL4$L! A0#
M%     @ LX!R51&>^+\E!0  Y"X  !4              ( !:0P  &%C:'8M
M,C R,C$Q,31?<')E+GAM;%!+ 0(4 Q0    ( +. <E4 5+C@+A@  +2Y   4
M              "  <$1  !A8VAV+3AK7S(P,C(Q,3$T+FAT;5!+ 0(4 Q0
M   ( +. <E4ARUWH]$H  ,)X @ 1              "  2$J  !A8VAV+65X
M,3 Q7S4T+FAT;5!+ 0(4 Q0    ( +. <E7:R&N?0U,  +$_ P 1
M      "  41U  !A8VAV+65X,3 R7S4S+FAT;5!+ 0(4 Q0    ( +. <E6M
M@FM'D%4  *88 @ 0              "  ;;(  !A8VAV+65X-#%?-34N:'1M
M4$L! A0#%     @ LX!R5<DS:B,,$P  N%4  !               ( !=!X!
G &%C:'8M97@Y.3%?-BYH=&U02P4&      @ "  ! @  KC$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
